Application No.: 10/812,075

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

- 1. (canceled).
- 2. (currently amended): A compound of Formula (I):

wherein Q is:

and wherein R1 is selected from the group consisting of:

(i) C₁₋₈ alkyl, and

 $C_{1.8}$ alkyl substituted by substituent(s) independently selected from the group consisting of:

·halogen,

•oxo,

•C₁₋₅ alkoxy,

•C1-5 alkoxy substituted by carbocyclic aryl,

•C₁₋₅ alkylcarbonyloxy,

carbocyclic aryloxy,

Application No.: 10/812,075

 carbocyclic aryloxy substituted by substituent(s) independently selected from the group consisting of:

••halogen,

••nitro.

••C₁₋₅ alkyl, and

••C₁₋₅ alkoxy,

·heterocyclyloxy,

•heterocyclyloxy substituted by C1-5 alkyl,

C₁₋₅ alkoxycarbonyl,

mono-C₁₋₅ alkylaminocarbonyl,

*di-C1-5 alkylaminocarbonyl,

•mono-C₁₋₅ alkylamino,

•mono-C1-5 alkylamino substituted by cyano,

•mono-C₁₋₅ alkylamino substituted by carbocyclic aryl,

•di-C₁₋₅ alkylamino,

•di-C1-5 alkylamino substituted by cyano,

di-C₁₋₅ alkylamino substituted by carbocyclic aryl,

•mono-carbocyclic arylamino,

·mono-carbocyclic arylamino substituted by halogen,

•mono-carbocyclic arylamino substituted by C₁₋₅ alkyl,

·di-carbocyclic arylamino,

di-carbocyclic arylamino substituted by halogen,

 $\hbox{$^{\bullet}$di-carbocyclic arylamino substituted by $C_{1.5}$-alkyl}, \\$

AMENDMENT UNDER 37 C.F.R. § 1.111 Application No.: 10/812,075

```
•C<sub>1-5</sub> alkoxycarbonylamino,
```

·carbocyclic arylcarbonylamino,

·carbocyclic arylsulfonylamino,

•carbocyclic arylsulfonylamino substituted C1-5 alkyl,

C₁₋₅ alkylthio,

 ${}^{\bullet}C_{1\text{--}5}$ alkylthio substituted by substituent(s) independently selected from

the group consisting of:

••carbocyclic aryl,

..carbocyclic aryl substituted by halogen, and

••carbocyclic aryl substituted by C₁₋₅ alkoxy,

·carbocyclic arylthio,

·heterocyclylthio,

·heterocyclylthio substituted by nitro,

·heterocyclylthio substituted by C1-5 alkyl,

•C3-6 cycloalkyl,

•C3-6 cycloalkenyl,

carbocyclyl,

•carbocyclyl substituted by substituent(s) independently selected from the group consisting of:

.

••halogen,
••C₁₋₅ alkyl,

••C₁₋₅ alkoxy,

••C2-5 alkenyl, and

Application No.: 10/812,075

••C₂₋₅ alkenyl substituted by substituent(s) independently selected from the group consisting of:

· · · carbocyclic aryl, and

•••carbocyclic aryl substituted by C₁₋₅ alkylsulfinyl,

·carbocyclic aryl,

 carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:

- ··halogen.
- ••hydroxy,
- ••nitro.
- ••C₁₋₅ alkyl,

••C₁₋₅ alkyl substituted by substituent(s) independently selected from the group consisting of:

- •••oxo,
- ...carbocyclic aryl, and
- · · · heterocyclyl,
- ••C2-5 alkenyl,
- ••C1-5 alkoxy,
- ••C1-5 alkoxy substituted by halogen,
- ••C1-5 alkoxy substituted by carbocyclic aryl,
- ··carbocyclic aryloxy,
- ··mono-carbocyclic arylaminocarbonyl,
- ••mono-carbocyclic arylaminocarbonyl substituted by halogen,

Attorney Docket No.: Q74855

AMENDMENT UNDER 37 C.F.R. § 1.111

Application No.: 10/812,075

··di-carbocyclic arylaminocarbonyl,

··di-carbocyclic arylaminocarbonyl substituted by halogen,

··carbocyclic aryl, and

..heterocyclyl,

·heterocyclyl, and

•heterocyclyl substituted by substituent(s) independently selected from the group consisting of:

••C₁₋₅ alkyl,

••C1-5 alkyl substituted by carbocyclic aryl,

••C₁₋₅ alkoxy,

••C1-5 alkoxy substituted by carbocyclic aryl,

..carbocyclic aryl, and

••carbocyclic aryl substituted by halogen,

(ii) C2-7 alkenyl, and

C₂₋₇ alkenyl substituted by substituent(s) independently selected from the group consisting of:

carbocyclic aryl,

•carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:

••halogen,

..nitro, and

••C₁₋₅ alkoxy,

(iii) C2-5 alkynyl, and

Attorney Docket No.: Q74855

AMENDMENT UNDER 37 C.F.R. § 1.111

Application No.: 10/812,075

C2-5 alkynyl substituted by carbocyclic aryl,

(iv) C₃₋₁₂ cycloalkyl, and

C₃₋₁₂ cycloalkyl substituted by substituent(s) independently selected from the group consisting of:

•C₁₋₅ alkyl,

•C1-5 alkyl substituted by oxo,

•C1-5 alkyl substituted by carbocyclic aryl, and

·carbocyclic aryl,

- (v) carbocyclyl,
- (vi) carbocyclic aryl, and

 $car bocyclic\ aryl\ substituted\ by\ substituent(s)\ independently\ selected\ from$

•halogen,

the group consisting of:

•hydroxy,

·cyano,

·nitro.

carboxy,

·carbamoyl,

•C₁₋₁₀ alkyl,

•C₁₋₁₀ alkyl substituted by substituent(s) independently selected from the group consisting of:

··halogen,

••hydroxy,

Application No.: 10/812,075

••oxo,

··carbocyclic aryloxy,

· carbocyclic aryl, and

••carbocyclic arvl substituted by C1-5 alkyl,

•C₁₋₇ alkoxy,

•C₁₋₇ alkoxy substituted by substituent(s) independently selected from the group consisting of:

··halogen.

· carbocyclic aryl, and

..halogenated carbocyclic aryl,

•C2-5 alkenyloxy,

•C3-6 cycloalkoxy,

·carbocyclic aryloxy,

·carbocyclic aryloxy substituted by nitro,

•carbocyclic aryloxy substituted by C1-5 alkoxy,

•C₁₋₅ alkoxycarbonyl,

·mono-C1-5 alkylaminocarbonyl,

di-C₁₋₅ alkylaminocarbonyl,

•mono-C₁₋₅ alkylaminocarbonyl substituted by carbocyclic aryl,

•di-C₁₋₅ alkylaminocarbonyl substituted by carbocyclic aryl,

·amino,

·mono-C1-5 alkylamino,

•di-C1-5 alkylamino,

Application No.: 10/812,075

•mono-C1-5 alkylamino substituted by cyano,

•di-C1-5 alkylamino substituted by cyano,

C₂₋₅ alkynylcarbonylamino,

•C2-5 alkynylcarbonylamino substituted by carbocyclic aryl,

•C1-5 alkoxycarbonylamino,

•(carbocyclic aryl)NHC(O)NH,

(carbocyclic aryl)NHC(O)NH substituted by C₁₋₅ alkoxy,

•(carbocyclic aryl)NHC(O)NH substituted by haloganated C1-5 alkoxy,

·carbocyclic aryl azo,

•carbocyclic aryl azo substituted by mono-C1-5 alkylamino,

•carbocyclic aryl azo substituted by di-C1-5 alkylamino,

•C1-5 alkylthio,

•C1-5 alkylthio substituted by halogen,

·carbocyclic arylthio,

·carbocyclic arylthio substituted by nitro,

·carbocyclic arylthio substituted by cyano,

aminosulfonyl,

mono-C₁₋₅ alkylaminosulfonyl,

di-C₁₋₅ alkylaminosulfonyl,

·heterocyclylsulfonyl,

•C3-6 cycloalkyl,

•C3.6 cycloalkyl substituted by C1.5 alkyl,

·carbocyclic aryl,

Application No.: 10/812,075

·heterocyclyl, and

 heterocyclyl substituted by substituent(s) independently selected from the group consisting of:

••C₁₋₅ alkyl,

..carbocyclic aryl, and

.. halogenated carbocyclic aryl,

(vii) heterocyclyl, and

heterocyclyl substituted by substituent(s) independently selected from the group consisting of:

·halogen,

•nitro,

·amino,

•hydroxy,

•C₁₋₅ alkyl,

•C₁₋₅ alkyl substituted by substituent(s) independently selected from the group consisting of:

- ••halogen,
- ••hvdroxy,
- ••C₁₋₅ alkylthio,
- ••C1-5 alkylthio substituted by carbocyclic aryl,
- $\bullet \bullet C_{1-5}$ alkylthio substituted by halogenated carbocyclic aryl,
- ··carbocyclic aryl,
- ..carbocyclic aryl substituted by halogen, and

Application No.: 10/812,075

··heterocyclyl,

•C₁₋₅ alkoxy,

·carbocyclic aryloxy,

•carbocyclic aryloxy substituted by halogen,

carbocyclic aryloxy substituted by C₁₋₅ alkyl,

•carbocyclic aryloxy substituted by C1-5 alkoxy,

•mono-C₁₋₅ alkylamino,

•di-C₁₋₅ alkylamino,

•C₁₋₅ alkylthio,

•C2-5 alkenylthio,

·carbocyclic arylthio,

•carbocyclic arylthio substituted by C₁₋₅ alkoxycarbonyl,

 ${}^{\bullet}\mathrm{C}_{1\text{-}5} \text{ alkylsulfonyl},$

·carbocyclic arylsulfonyl,

•carbocyclic arylsulfonyl substituted by C₁₋₅ alkyl,

•C₁₋₅ alkoxycarbonyl,

•C1-5 alkoxycarbonyl substituted by carbocyclic aryl,

·carbocyclic aryl,

•carbocyclic aryl substituted by substituent(s) independently selected from

the group consisting of:

••halogen,

••nitro.

••C₁₋₅ alkyl, and

Attorney Docket No.: Q74855

AMENDMENT UNDER 37 C.F.R. § 1.111

Application No.: 10/812,075

••C1-5 alkyl substituted by halogen,

·heterocyclyl;

R₂ is selected from the group consisting of:

halogen, hydroxy, carboxy, carbamoyl, amino, $C_{1.5}$ alkyl, $C_{1.5}$ alkyl substituted by halogen, $C_{1.5}$ alkyl substituted by hydroxy, $C_{1.5}$ alkyl substituted by carboxy, $C_{1.5}$ alkyl substituted by carbamoyl, $C_{1.5}$ alkoxy, $C_{1.5}$ alkoxy substituted by halogen, -NHNH₂, -NHNHBoc, -N(R_{2a})(R_{2b}), morpholino, 4-acetyl-piperazyl, or 4-phenyl-piperazyl, wherein R_{2a} is hydrogen or $C_{1.5}$ alkyl and R_{2b} is $C_{1.5}$ alkyl, $C_{3.6}$ cycloalkyl, or $C_{1.5}$ alkyl substituted by substituent(s) independently selected from the group consisting of:

·halogen,

•hvdroxy,

·carboxy,

·carbamoyl,

C₁₋₅ alkoxy,

•amino,

-NHBoc,

•C3-6 cycloalkyl,

·carbocyclic aryl,

•carbocyclic aryl substituted by substituent(s) independently selected from

the group consisting of:

••halogen,

••C₁₋₅ alkyl,

Attorney Docket No.: Q74855 AMENDMENT UNDER 37 C.F.R. § 1.111

Application No.: 10/812,075

·heterocyclyl, and

C3.6 cycloalkyl, carbocyclic aryl, carbocyclic aryl substituted by substituent(s)

independently selected from the group consisting of:

·halogen,

·C1.5 alkyl.

C₁₋₅ alkoxy, and

•a group of Formula (V):

wherein Boc is carbamic acid tert-butyl ester and G is C1-5 alkyl or C1-5 alkyl substituted by substituent(s) independently selected from the group consisting of:

·carbocyclic aryl,

·halogenated carbocyclic aryl, and

carbocyclic aryl substituted by C₁₋₅ alkoxy;

Each T is independently selected from the group consisting of halogen, hydroxy,

carboxy, carbamoyl, amino, cyano, nitro, C1-5 alkyl, C1-5 alkyl substituted by halogen, C1-5 alkyl substituted by hydroxy, C1-5 alkyl substituted by carboxy, C1-5 alkyl substituted by carbamoyl, C2-5 alkenyl, C2-5 alkynyl, C3-6 cycloalkyl, C1-5 alkoxy, C1-5 alkoxy substituted by halogen, carbocyclic aryl, heterocyclyl, and

 $-N(R_{2a})(R_{2b});$

p is 0, 1, 2, 3, 4 or 5;

Attorney Docket No.: O74855

AMENDMENT UNDER 37 C.F.R. § 1.111 Application No.: 10/812.075

wherein L is:

wherein R₃ and R₄ are independently hydrogen or C₁₋₅ alkyl; and A and B are independently a single bond, -CH₂-, or -(CH₂)₂-;

and

Y represents:

-C(O)NR₅-, -C(S)NR₅-, -C(O)O-, -S(O)₂-, -C(O)-, -C(S)-, a single bond, or -CH₂-; wherein R₅ is hydrogen or C₁₋₅ alkyl, or when Y is -C(O)NR₅- then R₅ and R₁ together with the nitrogen atoms to which each is they are bonded form forms a heterocyclyl group;

> wherein carbocyclic aryl is phenyl, naphthyl, or anthranyl; <u>mono-carbocyclic arylamino is mono-phenylamino;</u>

carbocyclyl is 1,2,3,4-tetrahydronaphthyl, 1-oxo-indanyl, 9-fluorenyl, 9H-fluorenyl, 9-oxo-9H-fluorenyl, adamantly, bicyclo[2.2.1]heptenyl, bicyclo[2.2.1]heptyl, indanyl, indenyl, or menthyl;-

heterocyclyl is 1,2,3-triazolyl, 1*H*-indolyl, 1*H*-pyrrolyl, 2,3-dihydro-1-oxo-isoindolyl, 2,3-dihydro-benzo[1,4]dioxinyl, 2,3-dihydro-benzofuryl, 2,4-dihydro-3-oxo-pyrazolyl, 2*H*-benzopyranyl, 2-oxo-benzopyranyl, 3,4-dihydro-2*H*-benzo[b][1,4]dioxepinyl, 4,5,6,7-tetrahydro-benzo[b]thienyl, 4*H*-benzo[1,3]dioxinyl, 4-oxo-1,5,6,7-tetrahydro-indolyl, 4-oxo-benzopyranyl, 9*H*-carbazolyl, 9*H*-xanthenyl, azetidinyl, benzo[1,3]dioxolyl, benzo[2,1,3]oxadiazolyl, benzo[1,2,5]oxadiazolyl,

Application No.: 10/812,075

benzo[2,1,3]thiadiazolyl, benzo[b]thienyl, benzofuryl, benzothiazolyl, furyl, imidazo[2,1-b]thiazolyl, imidazolyl, isoxazolyl, morpholino, morpholinyl, oxazolyl, phenanthro[9,10-d]oxazolyl, piperidyl, pyrazolyl, pyridyl, pyrimidyl, quinolyl, quinoxalyl, tetrahydrofuryl, thiazolyl, or thienyl; and

heterocyclyloxy is pyridinyloxy or 1H-pyrazolyloxy; and

halogen is fluoro, chloro, bromo, or iodo;

or a pharmaceutically acceptable salt thereof.

3-56. (canceled).

57. (previously presented): The compound according to claim 2 selected from the group consisting of:

 $N^2\hbox{-(cis-4-{[(5-bromo-1H-indol-3-yl)methyl]amino}} cyclohexyl)-N^4, N^4-methyl]$

dimethylpyrimidine-2,4-diamine;

 $N^2\hbox{-[cis-4-(\{[5-(4-fluorophenyl]pyridin-3-yl]methyl\}amino)} cyclohexyl]-N^4,N^4-dimethylpyrimidine-2,4-diamine;$

 $ethyl\ 4,6-dichloro-3-\{[(cis-4-\{[4-(dimethylamino)pyrimidin-2-yl]amino\}-cyclohexyl)amino]methyl\}-1H-indole-2-carboxylate;$

 N^2 -(cis-4-{[(2,6-dimethoxybenzyl)amino]methyl}cyclohexyl)- N^4 , N^4 -dimethylpyrimidine-2,4-diamine;

 $N^2-(cis-4-\{[(2-ethoxybenzyl)amino]methyl\}cyclohexyl)-N^4, N^4-dimethylpyrimidine-2, 4-diamine;$

 $N^2\mbox{-[cis-4-(\{[(4-methoxy-l-naphthyl)methyl]amino}]methyl)cyclohexyl]-N^4,} N^4-dimethylpyrimidine-2,4-diamine;}$

Application No.: 10/812,075

 $N^2-[cis-4-(\{[(5-methoxy-1H-indol-3-yl)methyl]amino\}methyl)cyclohexyl]-N^4,N^4-dimethylpyrimidine-2,4-diamine;$

 $N^2-[cis-4-(\{[(2-methoxy-1-naphthyl)methyl]amino\}methyl)cyclohexyl]-N^4,N^4-dimethylpyrimidine-2,4-diamine;$

4-bromo-2-({[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}-

 $cyclohexyl) methyl] amino\} methyl) - 6 - methoxyphenol;\\$

 N^2 -[cis-4-({[(5-bromo-1H-indol-3-yl)methyl]amino}methyl)eyclohexyl]- N^4 . N^4 -dimethylpyrimidine-2,4-diamine;

N²-(cis-4-{[(2,4-dimethoxybenzyl)amino]methyl}cyclohexyl)-N⁴,N⁴-

dimethylpyrimidine-2,4-diamine;

 N^4,N^4 -dimethyl- N^2 -(cis-4-{[(2,3,4-trimethoxybenzyl)amino]methyl}-cvclohexyl)pyrimidine-2,4-diamine;

 N^2 -(cis-4-{[(3-ethoxy-4-methoxybenzyl)amino]methyl}cyclohexyl)- N^4 , N^4 -dimethylpyrimidine-2,4-diamine;

N⁴,N⁴-dimethyl-N²-(cis-4-{[({3-[4-(trifluoromethyl)phenyl]-1H-pyrazol-4yl}methyl)amino]methyl}cyclohexyl)pyrimidine-2,4-diamine;

 $N^4,N^4-dimethyl-N^2-(cis-4-\{[(3,4,5-trimethoxybenzyl)amino]methyl\}-\\ eyclohexyl)pyrimidine-2,4-diamine;$

 $\label{eq:continuous} $$4-(\{[cis-4-\{[4-(dimethylamino)pyrimidin-2-yl]amino\}cyclohexyl)-$$ methyl]amino\}methyl]-2-iodo-6-methoxyphenol;$

 $\label{lem:condition} $$4-(\{[(cis-4-\{[4-(dimethylamino)pyrimidin-2-yl]amino\}cyclohexyl)methyl]-amino\}methyl)-2,6-dimethylphenol;$

Application No.: 10/812,075

 $N^2\text{-(cis-4-\{[(5\text{-bromo-2,4-dimethoxybenzyl})amino]methyl}\} cyclohexyl)-N^4, N^4-methyl \} cyclohexyl)-N^4, N^4-methyl \} cyclohexyl - N^4 + N$

dimethylpyrimidine-2,4-diamine;

 $N^2\hbox{-(cis-}4\hbox{-}\{[(5\hbox{-bromo-}2\hbox{-methoxybenzyl})amino]methyl}\}cyclohexyl)\hbox{-}N^4\hbox{-}N^4\hbox{-}N^4$

dimethylpyrimidine-2,4-diamine;

 $N^2\hbox{-[cis-4-(\{[4-(diethylamino)benzyl]amino\}methyl)cyclohexyl]-}N^4,N^4-$

dimethylpyrimidine-2,4-diamine;

 $N^2\hbox{-[cis-4-(\{[(9-ethyl-9H-carbazol-3-yl)methyl]amino\}methyl)cyclohexyl]-}N^4\hbox{-}N^4\hbox{-}light and N^2\hbox{-[cis-4-(\{[(9-ethyl-9H-carbazol-3-yl)methyl]amino\}methyl)cyclohexyl]-}N^4\hbox{-}N^4\hbox{-}light and N^2\hbox{-}light and N^2\hbox{-}lig$

dimethylpyrimidine-2,4-diamine;

 N^2 -(cis-4-{[(4-isopropoxybenzyl)amino]methyl}cyclohexyl)- N^4 , N^4 -dimethylpyrimidine-2.4-diamine;

 $N^2\hbox{-(cis-4-{[(3,3-diphenylprop-2-en-1-yl)amino]}methyl}\ cyclohexyl)-N^4,N^4-methyl$

dimethylpyrimidine-2,4-diamine;

4-({[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-

amino}methyl)-2-ethoxyphenol;

 $N^2-\{cis-4-[(\{[4-(dimethylamino)-1-naphthyl]methyl\}amino)methyl]-cyclohexyl\}-N^4,N^4-dimethylpyrimidine-2,4-diamine;$

N⁴,N⁴-dimethyl-N²-(cis-4-{[(2,4,6-trimethoxybenzyl)amino]methyl}-

cyclohexyl)pyrimidine-2,4-diamine;

 $N^2\text{-}(cis-4\text{-}\{[(5\text{-bromo-}2\text{-ethoxybenzyl})amino]methyl}\}cyclohexyl)\text{-}N^4\text{-$

dimethylpyrimidine-2,4-diamine;

 $N^2\text{-}(cis-4-\{[(2,4\text{-}dimethoxy-3-methylbenzyl)amino]methyl\}cyclohexyl)-N^4,N^4-\\ dimethylpyrimidine-2,4-diamine;$

AMENDMENT UNDER 37 C.F.R. § 1.111

Application No.: 10/812,075

 $N^2-(cis-4-\{[(2,5-diethoxybenzyl)amino]methyl\}cyclohexyl)-N^4, N^4-dimethylpyrimidine-2,4-diamine;$

 $N^2-(cis-4-\{[(2,4-diethoxybenzyl)amino]methyl\}cyclohexyl)-N^4, \\ N^4-dimethylpyrimidine-2,4-diamine;$

 $N^2\hbox{-(cis-4-\{[(3,5-dibromo-2-methoxybenzyl)amino]methyl\}cyclohexyl)-}N^4,N^4-(cis-4-\{[(3,5-dibromo-2-methoxybenzyl)amino]methyl\}cyclohexyl)-N^4,N^4-(cis-4-\{[(3,5-dibromo-2-methoxybenzyl)amino]methyl\}cyclohexyl)-N^4,N^4-(cis-4-\{[(3,5-dibromo-2-methoxybenzyl)amino]methyl\}cyclohexyl)-N^4,N^4-(cis-4-\{[(3,5-dibromo-2-methoxybenzyl)amino]methyl]cyclohexyl)-N^4,N^4-(cis-4-\{[(3,5-dibromo-2-methoxybenzyl)amino]methyl]cyclohexyl)-N^4,N^4-(cis-4-($

dimethylpyrimidine-2,4-diamine;

 $N^4, N^4 \hbox{-dimethyl-} N^2 \hbox{-(cis-4-{[(2,4,5-triethoxybenzyl)amino]methyl}-}$

cyclohexyl)pyrimidine-2,4-diamine;

N⁴.N⁴-dimethyl-N²-(cis-4-{[(2,4,5-trimethoxybenzyl)amino]methyl}-

cyclohexyl)pyrimidine-2,4-diamine;

 $N^2-[cis-4-(\{[2-(allyloxy)benzyl]amino\}methyl)cyclohexyl]-N^4,N^4-dimethylpyrimidine- \\ 2.4-diamine;$

 $N^4, N^4 - dimethyl - N^2 - [cis-4 - (\{[(1-methyl-1H-indol-3-yl)methyl]amino\} - (1-methyl-1H-indol-3-yl)methyl]$

methyl)cyclohexyl]pyrimidine-2,4-diamine;

 $N^2-[cis-4-(\{[(7-methoxy-1,3-benzodioxol-5-yl)methyl]amino\} methyl)-cyclohexyl]-\\ N^4,N^4-dimethylpyrimidine-2,4-diamine;$

 $N^2\hbox{-(cis-4-{[(3-bromo-4,5-dimethoxybenzyl)amino]methyl}} cyclohexyl)-N^4,N^4-methyl$

dimethylpyrimidine-2,4-diamine;

N²-(cis-4-{[(4-methoxy-3-methylbenzyl)amino]methyl}cyclohexyl)-N⁴,N⁴-

dimethylpyrimidine-2,4-diamine;

 N^2 -(cis-4-{[(2-bromo-4,5-dimethoxybenzyl)amino]methyl}cyclohexyl)- N^4 , N^4 -dimethylpyrimidine-2,4-diamine;

Application No.: 10/812,075

 $N^2\text{-}(cis-4-\{[(3,4\text{-}dimethoxybenzyl)amino]methyl}\}cyclohexyl)-N^4,N^4-(cis-4-\{[(3,4\text{-}dimethoxybenzyl)amino]methyl}\}cyclohexyl)-N^4,N^4-(cis-4-\{[(3,4\text{-}dimethoxybenzyl)amino]methyl}\}cyclohexyl)-N^4,N^4-(cis-4-\{[(3,4\text{-}dimethoxybenzyl)amino]methyl\}cyclohexyl)-N^4,N^4-(cis-4-\{[(3,4\text{-}dimethoxybenzyl)amino]methyl\}cyclohexyl)-N^4,N^4-(cis-4-\{[(3,4\text{-}dimethoxybenzyl)amino]methyl]cyclohexyl)-N^4,N^4-(cis-4-\{[(3,4\text{-}dimethoxybenzyl)amino]methyl]cyclohexyl)-N^4,N^4-(cis-4-\{[(3,4\text{-}dimethoxybenzyl)amino]methyl]cyclohexyl)-N^4,N^4-(cis-4-\{[(3,4\text{-}dimethoxybenzyl)amino]methyl]cyclohexyl)-N^4,N^4-(cis-4-\{[(3,4\text{-}dimethoxybenzyl)amino]methyl]cyclohexyl)-N^4,N^4-(cis-4-\{[(3,4\text{-}dimethoxybenzyl)amino]methyl]cyclohexyl)-N^4,N^4-(cis-4-\{[(3,4\text{-}dimethoxybenzyl)amino]methyl]cyclohexyl)-N^4,N^4-(cis-4-\{[(3,4\text{-}dimethoxybenzyl)amino]methyl]cyclohexyl)-N^4,N^4-(cis-4-\{[(3,4\text{-}dimethoxybenzyl)amino]methyl]cyclohexyl)-N^4,N^4-(cis-4-\{[(3,4\text{-}dimethoxybenzyl)amino]methyl]cyclohexyl)-N^4,N^4-(cis-4-\{[(3,4\text{-}dimethoxybenzyl)amino]methyl]cyclohexyl)-N^4,N^4-(cis-4-\{[(3,4\text{-}dimethoxybenzyl)amino]methyl]cyclohexyl)-N^4,N^4-(cis-4-\{[(3,4\text{-}dimethoxybenzyl)amino]methyl]cyclohexyl)-N^4,N^4-(cis-4-\{[(3,4\text{-}dimethoxybenzyl)amino]methyl]cyclohexyl)-N^4,N^4-(cis-4-\{[(3,4\text{-}dimethoxybenzyl)amino]methyl]cyclohexyl)-N^4,N^4-(cis-4-\{[(3,4\text{-}dimethoxybenzyl)amino]methyl]cyclohexyl)-N^4,N^4-(cis-4-\{[(3,4\text{-}dimethoxybenzyl)amino]methyl)-N^4,N^4-(cis-4-\{[(3,4\text{-}dimethoxybenzyl)amino]methyl)-N^4,N^4-(cis-4-\{[(3,4\text{-}dimethoxybenzyl)amino]methyl)-N^4,N^4-(cis-4-\{[(3,4\text{-}dimethoxybenzyl)amino]methyl)-N^4,N^4-(cis-4-\{[(3,4\text{-}dimethoxybenzyl)amino]methyl)-N^4,N^4-(cis-4-\{[(3,4\text{-}dimethoxybenzyl)amino]methyl)-N^4,N^4-(cis-4-\{[(3,4\text{-}dimethoxybenzyl)amino]methyl)-N^4,N^4-(cis-4-\{[(3,4\text{-}dimethoxybenzyl)amino]methyl)-N^4,N^4-(cis-4-\{[(3,4\text{-}dimethoxybenzyl)amino]methylamino]methylamino]methylamino(cis-4-\{[(3,4\text{-}dimethoxybenzyl)amino]methylamino(cis-4-\{[(3,4\text{-}dimethoxybenzyl)amino]methylamino(cis-4-\{[(3,4\text{-}dimethoxybenzyl)a$

dimethylpyrimidine-2,4-diamine;

 N^2 -(cis-4-{[(4-methoxy-2,5-dimethylbenzyl)amino]methyl}cyclohexyl)- N^4 , N^4 -dimethylpyrimidine-2,4-diamine;

3-[[4-({[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]amino}methyl)phenyl](methyl)amino]propanenitrile;

 N^2 -{cis-4-[({4-[(4-bromobenzyl)oxy]benzyl}amino)methyl]cyclohexyl}- N^4 , N^4 -dimethylpyrimidine-2,4-diamine;

 N^2 -(cis-4-{[(3,5-dibromo-2-ethoxybenzyl)amino]methyl}cyclohexyl)- N^4 , N^4 -dimethylpyrimidine-2,4-diamine;

 $\label{eq:N2-lambda} N^2\mbox{-}[4\mbox{-}(4\mbox{-}bromo\mbox{-}2\mbox{-}trifluoromethoxy-benzyl)amino-cyclohexyl]-}N^4\mbox{-}N^4\mbox{-}dimethyl-pyrimidine-2,4-diamine;}$

 $N^2-\{cis-4-[2-(4-bromo-2-trifluoromethoxy-phenyl)-ethylamino]-cyclohexyl\}-N^4,N^4-dimethyl-pyrimidine-2,4-diamine; and$

 $N^2-\{cis-4-[(4-bromo-2-trifluoromethoxy-benzyl)amino-methyl]-cyclohexyl\}-N^4,N^4-dimethyl-pyrimidine-2,4-diamine;$

or a pharmaceutically acceptable salt thereof.

58. (previously presented): The compound according to claim 57 selected from the group consisting of:

ethyl 4,6-dichloro-3-{[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}-cyclohexyl)amino]methyl}-1H-indole-2-carboxylate;

 $N^2-[cis-4-(\{[(4-methoxy-1-naphthyl)methyl]amino\}methyl)cyclohexyl]-N^4,N^4-dimethylpyrimidine-2,4-diamine;$

Attorney Docket No.: Q74855

AMENDMENT UNDER 37 C.F.R. § 1.111

Application No.: 10/812,075

 $N^2-[cis-4-(\{[(2-methoxy-1-naphthyl)methyl]amino\}methyl)cyclohexyl]-N^4,N^4-\\ dimethylpyrimidine-2,4-diamine;$

4-bromo-2-({[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}-

cyclohexyl)methyl]amino}methyl)-6-methoxyphenol;

 $N^2-[cis-4-(\{[(5-bromo-1H-indol-3-yl)methyl]amino\} methyl)cyclohexyl]-N^4,N^4-dimethylpyrimidine-2,4-diamine;$

 $N^4,N^4-dimethyl-N^2-(cis-4-\{[(2,3,4-trimethoxybenzyl)amino]methyl\}-\\ cyclohexyl)pyrimidine-2,4-diamine;$

 $N^2\mbox{-(cis-4-{[(3-ethoxy-4-methoxybenzyl)amino]methyl}}\ eyclohexyl)-N^4, N^4-dimethylpyrimidine-2, 4-diamine;$

 $N^4,N^4-dimethyl-N^2-(cis-4-\{[(3-[4-(trifluoromethyl)phenyl]-1H-pyrazol-4-yl\}methyl)amino]methyl\}cyclohexyl)pyrimidine-2,4-diamine;$

4-({[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]amino}methyl)-2-iodo-6-methoxyphenol;

4-({[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]amino}methyl)-2,6-dimethylphenol;

N²-(cis-4-{[(5-bromo-2,4-dimethoxybenzyl)amino]methyl}cyclohexyl)-N⁴,N⁴-dimethylpyrimidine-2,4-diamine;

 $N^2\mbox{-(cis-4-{[(5-bromo-2-methoxybenzyl)amino]methyl}-cyclohexyl)-}N^4\mbox{-}N^4\mbox{-}$ $\mbox{dimethylpyrimidine-2,4-diamine;}$

 $N^2-[cis-4-(\{[(9-ethyl-9H-carbazol-3-yl]methyl]amino\}methyl)cyclohexyl]-N^4,N^4-dimethylpyrimidine-2,4-diamine;$

Application No.: 10/812,075

dimethylpyrimidine-2,4-diamine;

N⁴.N⁴-dimethyl-N²-(cis-4-{[(2,4,6-trimethoxybenzyl)amino]methyl}-

cyclohexyl)pyrimidine-2,4-diamine;

 N^2 -(cis-4-{[(5-bromo-2-ethoxybenzyl)amino]methyl}cyclohexyl)- N^4 , N^4 -

dimethylpyrimidine-2,4-diamine;

 $N^2\text{-(cis-4-}\{[(2,4\text{-dimethoxy-3-methylbenzyl})amino]methyl\}cyclohexyl)-N^4,N^4-(2,4\text{-dimethoxy-3-methylbenzyl})amino]methyl\}cyclohexyl)-N^4,N^4-(2,4\text{-dimethoxy-3-methylbenzyl})amino]methyl]cyclohexyl)-N^4,N^4-(2,4\text{-dimethoxy-3-methylbenzyl})amino]methyl]cyclohexyl)-N^4,N^4-(2,4\text{-dimethoxy-3-methylbenzyl})amino]methyl]cyclohexyl)-N^4,N^4-(2,4\text{-dimethoxy-3-methylbenzyl})amino]methyl]cyclohexyl)-N^4,N^4-(2,4\text{-dimethoxy-3-methylbenzyl})amino]methyl]cyclohexyl)-N^4,N^4-(2,4\text{-dimethoxy-3-methylbenzyl})amino]methyl]cyclohexyl)-N^4,N^4-(2,4\text{-dimethoxy-3-methylbenzyl})amino]methyl]cyclohexyl)-N^4,N^4-(2,4\text{-dimethoxy-3-methylbenzyl})amino]methyl]cyclohexyl)-N^4,N^4-(2,4\text{-dimethoxy-3-methylbenzyl})amino]methyl]cyclohexyl)-N^4,N^4-(2,4\text{-dimethoxy-3-methylbenzyl})amino]methyl]cyclohexyl)-N^4,N^4-(2,4\text{-dimethoxy-3-methylbenzyl})amino]methyl]cyclohexyl)-N^4,N^4-(2,4\text{-dimethoxy-3-methylbenzyl})amino]methyl]cyclohexyl)-N^4,N^4-(2,4\text{-dimethoxy-3-methylbenzyl})amino]methyl]cyclohexyl)-N^4,N^4-(2,4\text{-dimethoxy-3-methylbenzyl})amino]methylbenzyl]cyclohexyl)-N^4,N^4-(2,4\text{-dimethoxy-3-methylbenzyl})amino]methylbenzyl]cyclohexyll$

dimethylpyrimidine-2,4-diamine;

 N^2 -(cis-4-{[(2,5-diethoxybenzyl)amino]methyl}cyclohexyl)- N^4 , N^4 -dimethylpyrimidine-2.4-diamine:

 $N^2\text{-}(cis\text{-}4\text{-}\{[(3,5\text{-}dibromo\text{-}2\text{-}methoxybenzyl})amino]methyl\}cyclohexyl)\text{-}N^4\text{,}N^4\text{-}N^$

dimethylpyrimidine-2,4-diamine;

N⁴,N⁴-dimethyl-N²-(cis-4-{[(2,4,5-triethoxybenzyl)amino]methyl}-

cyclohexyl)pyrimidine-2,4-diamine;

 $N^2-[cis-4-(\{[2-(allyloxy)benzyl]amino\}methyl)cyclohexyl]-N^4, N^4-dimethylpyrimidine- \\ 2.4-diamine:$

 $N^2-[cis-4-(\{[(7-methoxy-1,3-benzodioxol-5-yl)methyl]amino\} methyl)-cyclohexyl]-cyclohex$

N4,N4-dimethylpyrimidine-2,4-diamine;

N2-(cis-4-{[(3-bromo-4,5-dimethoxybenzyl)amino]methyl}cyclohexyl)-N4,N4-

dimethylpyrimidine-2,4-diamine;

 $N^2-\{cis-4-[2-(4-bromo-2-trifluoromethoxy-phenyl)-ethylamino]-cyclohexyl\}-N^4, N^4-dimethyl-pyrimidine-2, 4-diamine; and$

Application No.: 10/812,075

 $N^2-\{cis-4-[(4-bromo-2-trifluoromethoxy-benzyl)amino-methyl]-cyclohexyl\}-N^4,N^4-dimethyl-pyrimidine-2,4-diamine;$

or a pharmaceutically acceptable salt thereof.

59.-62. (canceled).

63. (previously presented): The compound according to claim 2 selected from the group consisting of:

N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-3-methoxybenzamide;
3-bromo-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-benzamide;

 $N-(cis-4-\{[4-(dimethylamino)pyrimidin-2-yl]amino\} cyclohexyl)-2,1,3-benzoxadiazole-5-carboxamide;$

3-chloro-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-benzamide;

 $\label{lem:lem:lem:lem:lem:hero} \mbox{4-chloro-N-(cis-4-\{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-benzamide;}$

4-chloro-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-3-

nitrobenzamide;

3,5-dichloro-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}-

cyclohexyl)benzamide;

 $3, 4-dichloro-N-(cis-4-\{[4-(dimethylamino)pyrimidin-2-yl]amino\}-1, 4-dichloro-N-(cis-4-\{[4-(dimethylamino)pyrimidin-2-yl]amino]-1, 4-dichloro-N-(cis-4-\{[4-(dimethylamino)pyrimidin-2-yl]amino]-1, 4-dichloro-N-(cis-4-(dimethylamino)pyrimidin-2-yl]-1, 4-dimethylamino-1, 4-dim$

cyclohexyl)benzamide;

N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2,2-diphenylacetamide;

N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-3,4-difluorobenzamide;

N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-3,5-difluorobenzamide;

N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-3-fluoro-5-

(trifluoromethyl)benzamide;

AMENDMENT UNDER 37 C.F.R. § 1.111

Application No.: 10/812,075

nitrobenzamide;

 $N-(cis-4-\{[4-(dimethylamino)pyrimidin-2-yl]amino\} cyclohexyl)-4-methyl-3-$

N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-3-nitrobenzamide;

N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2-phenoxybutanamide;

N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-3-methylbenzamide;

N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-3-

(trifluoromethoxy)benzamide;

4-bromo-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-3-methylbenzamide;

N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-3-iodobenzamide;

N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2,5-dimethyl-3-

furamide;

3-chloro-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-4-

fluorobenzamide;

N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-3,5-

dimethoxybenzamide;

N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-3,5-

bis(trifluoromethyl)benzamide;

N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-4-fluoro-3-methylbenzamide;

2,5-dichloro-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}-cyclohexyl)thiophene-3-carboxamide;

Attorney Docket No.: Q74855

AMENDMENT UNDER 37 C.F.R. § 1.111 Application No.: 10/812,075

1-benzyl-3-tert-butyl-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}-cyclohexyl)-1H-pyrazole-5-carboxamide;

N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2-(1-naphthyl)acetamide;

2-(4-chlorophenoxy)-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}-cvclohexyl)acetamide;

 $3-(2-chloro-6-fluorophenyl)-N-(cis-4-\{[4-(dimethylamino)pyrimidin-2-yl]amino\}cyclohexyl)-5-methylisoxazole-4-carboxamide;$

 $\label{eq:N-constraint} N-(cis-4-\{[4-(dimethylamino)pyrimidin-2-yl]amino\} cyclohexyl)-4-fluoro-3-(trifluoromethyl)benzamide;$

 $N-(cis-4-\{[4-(dimethylamino)pyrimidin-2-yl]amino\} cyclohexyl)-5-methyl-2-phenyl-2H-1,2,3-triazole-4-carboxamide;$

N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2-(4-methoxyphenoxy)-5-nitrobenzamide;

 $N-(cis-4-\{[4-(dimethylamino)pyrimidin-2-yl]amino\} cyclohexyl)-2-phenoxyacetamide;\\$

N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-quinoxaline-2carboxamide:

N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-3-

(trifluoromethyl)benzamide;

 $N-(cis-4-\{[4-(dimethylamino)pyrimidin-2-yl]amino\}cyclohexyl)-2-\\ (pentafluorophenoxy)acetamide;$

Application No.: 10/812,075

2-(3-chlorophenoxy)-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-

yl]amino}cyclohexyl)acetamide;

3-(2,6-dichlorophenyl)-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-5-methylisoxazole-4-carboxamide;

N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2-

phenoxynicotinamide;

N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2-(4methylphenoxy)nicotinamide;

 $N-(cis-4-\{[4-(dimethylamino)pyrimidin-2-yl]amino\} cyclohexyl)-4-\\ [(dipropylamino)sulfonyl]benzamide;$

 $\label{lem:condition} 2-(4-chlorophenoxy)-N-(cis-4-\{[4-(dimethylamino)pyrimidin-2-yl]amino\}cyclohexyl)-2-methylpropanamide;$

2-(2,3-dihydro-1-benzofuran-5-yl)-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-1,3-thiazole-4-carboxamide;

3-tert-butyl-1-(2,4-dichlorobenzyl)-N-(cis-4-{[4-(dimethylamino)pyrimidin-2yllamino}cyclohexyl)-1H-pyrazole-5-carboxamide;

6-chloro-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2H-chromene-3-carboxamide;

N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2-(2-thienyl)-1,3-thiazole-4-carboxamide;

 $\label{eq:continuous} 5-(4-chloro-2-nitrophenyl)-N-(cis-4-\{[4-(dimethylamino)pyrimidin-2-yl]amino\}cyclohexyl)-2-furamide;$

N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-5-iodo-2-furamide;

Application No.: 10/812,075

N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-5-(4-methyl-2-nitrophenyl)-2-furamide;

 $N-(cis-4-\{[4-(dimethylamino)pyrimidin-2-yl]amino\} cyclohexyl)-5-nitrothiophene-2-carboxamide;\\$

N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-3-methyl-4-nitrobenzamide;

N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-3-methoxy-4nitrobenzamide;

1-benzyl-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-1H-indole-3-carboxamide;

 $3\hbox{-acetyl-N-(cis-4-\{[4-(dimethylamino)pyrimidin-2-yl]amino}\} cyclohexyl)-benzamide;$

5-bromo-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2-furamide;

5-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}-cyclohexyl)-2-furamide:

4,5-dibromo-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}-cyclohexyl)thiophene-2-carboxamide;

2-(3,5-di-tert-butyl-4-hydroxyphenyl)-N-(cis-4-{[4-(dimethylamino)-pyrimidin-2-yl]amino}cyclohexyl)acetamide;

 $N^2, N^6-dibenzoyl-N-(cis-4-\{[4-(dimethylamino)pyrimidin-2-yl]amino\}-cyclohexyl)] ysinamide; \\$

3-(dimethylamino)-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}-cyclohexyl)benzamide;

AMENDMENT UNDER 37 C.F.R. § 1.111

Application No.: 10/812,075

4,5-dibromo-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}-cyclohexyl)-2-furamide;

 $N-(cis-4-\{[4-(dimethylamino)pyrimidin-2-yl]amino\} eyclohexyl)-2-(1H-indol-3-yl)acetamide; \\$

 $N-(cis-4-\{[4-(dimethylamino)pyrimidin-2-yl]amino\} cyclohexyl)-2-(5-methyl-2-phenyl-1,3-thiazol-4-yl)acetamide;$

 $\label{eq:N-condition} N-(cis-4-\{[4-(dimethylamino)pyrimidin-2-yl]amino\}cyclohexyl)-2-(1H-indol-3-yl)-4-oxo-4-phenylbutanamide;$

4-(4-bromophenyl)-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}-cyclohexyl)-2-(1H-indol-3-yl)-4-oxobutanamide;

3,5-dichloro-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}-cyclohexyl)-2-[(3-phenylprop-2-ynoyl)amino]benzamide;

 $N-(cis-4-\{[4-(dimethylamino)pyrimidin-2-yl]amino\}cyclohexyl]-2-(1-methyl-1H-indol-3-yl]-4-(4-methylphenyl)-4-oxobutanamide;$

N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2-methyl-1-(3-morpholin-4-ylpropyl)-5-phenyl-1H-pyrrole-3-carboxamide;

N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-4-(4-nitrophenyl)butanamide;

 $N-(cis-4-\{[4-(dimethylamino)pyrimidin-2-yl]amino\} cyclohexyl)-2-(2-phenyl-1H-indol-3-yl)acetamide;$

 $N^2-benzoyl-N^5-(cis-4-\{[4-(dimethylamino)pyrimidin-2-yl]amino\}-cyclohexyl)-N^1,N^1-dipropylglutamamide;$

N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-3-phenoxybenzamide;

Application No.: 10/812,075

3-benzoyl-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}-cyclohexyl)benzamide;

 $N-(cis-4-\{[4-(dimethylamino)pyrimidin-2-yl]amino\} cyclohexyl)-2-(ethylthio)-2, 2-diphenylacetamide;$

N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-N'-[(1R)-1-(1-naphthyl)ethyl]phthalamide;

 $\label{lem:continuous} (2S)-2-(3-benzoylphenyl)-N-(cis-4-\{[4-(dimethylamino)pyrimidin-2-yl]amino\}cyclohexyl)propanamide;$

 $\label{eq:N-constraint} N-(cis-4-\{[4-(dimethylamino)pyrimidin-2-yl]amino\} cyclohexyl)-N,N-bis[(1S)-1-phenylethyl]phthalamide;$

 $N-(cis-4-\{[4-(dimethylamino)pyrimidin-2-yl]amino\} cyclohexyl)-2-\{(1E)-5-fluoro-2-methyl-1-[4-(methylsulfinyl)benzylidene]-1H-inden-3-yl\} acetamide;$

 $N-(cis-4-\{[4-(dimethylamino)pyrimidin-2-yl]amino\}cyclohexyl)-2-[4-(2-thienylcarbonyl)phenyl]propanamide; \\$

3-(benzyloxy)-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}-cyclohexyl)-4-methoxybenzamide;

 $N-(cis-4-\{[4-(dimethylamino)pyrimidin-2-yl]amino\} cyclohexyl)-2-methyl-1,5-diphenyl-1H-pyrrole-3-carboxamide;\\$

1-{2-[(2-chloro-6-fluorobenzyl)thio]ethyl}-N-(cis-4-{[4-(dimethylamino)-pyrimidin-2-yl]amino}cyclohexyl)-2-methyl-5-phenyl-1H-pyrrole-3-carboxamide;

N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2-phenoxybenzamide;

N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2-phenylquinoline-4carboxamide:

Application No.: 10/812,075

2-[4-(4-chlorophenyl)-2-phenyl-1,3-thiazol-5-yl]-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)acetamide;

 $N-(cis-4-\{[4-(dimethylamino)pyrimidin-2-yl]amino\} cyclohexyl)-1-[(4-methylphenyl)sulfonyl]-1H-pyrrole-3-carboxamide;$

 $N-(cis-4-\{[4-(dimethylamino)pyrimidin-2-yl]amino\} eyclohexyl)-5-(3-nitrophenyl)-2-furamide;\\$

 $\label{lem:condition} 3-chloro-N-(cis-4-\{[4-(dimethylamino)pyrimidin-2-yl]amino\}cyclohexyl)-4- \\ (isopropylsulfonyl)-5-(methylthio)thiophene-2-carboxamide;$

 $N-(cis-4-\{[4-(dimethylamino)pyrimidin-2-yl]amino\}cyclohexyl)-3-iodo-4-\\ (isopropylsulfonyl)-5-(methylthio)thiophene-2-carboxamide;$

N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-5-nitrothiophene-3-carboxamide;

N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-1-methyl-4-nitro-1Hpyrrole-2-carboxamide;

N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-4-nitrobenzamide;

N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-3,5-dimethyl-4-nitrobenzamide:

N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2-mesityl-2-oxoacetamide:

3,5-di-tert-butyl-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}-cyclohexyl)-4-hvdroxybenzamide:

4-chloro-N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyllbenzamide;

Attorney Docket No.: Q74855

AMENDMENT UNDER 37 C.F.R. § 1.111

Application No.: 10/812,075

 $(2E)-N-[(cis-4-\{[4-(dimethylamino)pyrimidin-2-yl]amino\}cyclohexyl)-methyl]-3-phenylacrylamide;$

4-chloro-N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-methyl]-3-nitrobenzamide;

 $\label{lem:condition} 2-(4-chlorophenyl)-N-[(cis-4-\{[4-(dimethylamino)pyrimidin-2-yl]amino\}-cyclohexyl)methyl]acetamide;$

3,5-dichloro-N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}-cyclohexyl)methyl]benzamide;

3,4-dichloro-N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}-cyclohexyl)methyl]benzamide;

 $\label{eq:N-constraint} N-[(cis-4-\{[4-(dimethylamino)pyrimidin-2-yl]amino\}cyclohexyl)methyl]-2,2-diphenylacetamide;$

 $2, 4-dichloro-N-[(cis-4-\{[4-(dimethylamino)pyrimidin-2-yl]amino\}-cyclohexyl)methyl]\\ 5-fluorobenzamide;$

N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-2-phenoxybutanamide;

 $\label{eq:N-loss} N-[(cis-4-\{[4-(dimethylamino)pyrimidin-2-yl]amino\}cyclohexyl) methyl]-2-phenylbutanamide;$

 $N-\{(cis-4-\{[4-(dimethylamino)pyrimidin-2-yl]amino\} cyclohexyl) methyl]-2-(3-methoxyphenyl) acetamide;$

N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-2-(4-methoxyphenyl)acetamide;

AMENDMENT UNDER 37 C.F.R. § 1.111

Application No.: 10/812,075

 $N-[(cis-4-\{[4-(dimethylamino)pyrimidin-2-yl]amino\}cyclohexyl)methyl]-3,5-bis(trifluoromethyl)benzamide;$

(2E)-N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-methyl]-3-(4-nitrophenyl)acrylamide;

2-(2-bromophenyl)-N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}-cyclohexyl)methyl]acetamide;

 $\label{eq:N-loss} N-[(cis-4-\{[4-(dimethylamino)pyrimidin-2-yl]amino\}cyclohexyl)methyl]-2-(propylthio)nicotinamide;$

N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-2-(1-naphthyl)acetamide;

N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-y1]amino}cyclohexyl)methyl]-9-oxo-9H-fluorene-4-carboxamide;

 $N-[(cis-4-\{[4-(dimethylamino)pyrimidin-2-yl]amino\} cyclohexyl) methyl]-2,4,6-trimethylbenzamide;\\$

2,4,6-trichloro-N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}-cyclohexyl)methyl]benzamide;

 $\label{eq:continuous} \end{cases} (2E)-3-(2-chlorophenyl)-N-[(cis-4-\{[4-(dimethylamino)pyrimidin-2-yl]amino\}cyclohexyl)methyl]acrylamide;$

N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-2-(2,3,6-trichlorophenyl)acetamide;

 $N-[(cis-4-\{[4-(dimethylamino)pyrimidin-2-yl]amino\}cyclohexyl)methyl]-2,3-diphenylpropanamide;$

Application No.: 10/812,075

 $N-[(cis-4-\{[4-(dimethylamino)pyrimidin-2-yl]amino\}cyclohexyl)methyl]-5-iodo-2-furamide; \\$

(2E)-N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-methyl]-3-(3-nitrophenyl)acrylamide;

 $\label{eq:N-condition} N-[(cis-4-\{[4-(dimethylamino)pyrimidin-2-yl]amino\}cyclohexyl)methyl]-3-oxoindane-1-carboxamide;$

 $\label{lem:continuous} 2-benzyl-N-[(cis-4-\{[4-(dimethylamino)pyrimidin-2-yl]amino\}cyclohexyl)-methyl]benzamide;$

2,2-bis(4-chlorophenyl)-N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]acetamide;

 $N-[(cis-4+\{[4-(dimethylamino)pyrimidin-2-yl]amino\}cyclohexyl)methyl]-3-methyl-4-nitrobenzamide;\\$

N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-3-methoxy-4-nitrobenzamide;

N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-2-[2-(trifluoromethoxy)phenyl]acetamide;

 $N-[(cis-4-\{[4-(dimethylamino)pyrimidin-2-yl]amino\}cyclohexyl)methyl]-9H-xanthene-9-carboxamide;$

2-(1-benzothien-3-yl)-N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]acetamide;

 $\label{eq:N-cyclohexyl-2-(4-fluoro-phenoxy)-1} N-[cis-4-(4-dimethylamino-pyrimidin-2-ylamino)-cyclohexyl]-2-(4-fluoro-phenoxy)-nicotinamide;$

Application No.: 10/812,075

N-[cis-4-(4-dimethylamino-pyrimidin-2-ylamino)-cyclohexyl]-C-(ethyl-phenyl-amino)-acetamide:

C-[cis-(4-chloro-phenyl)-ethyl-amino]-N-[4-(4-dimethylamino-pyrimidin-2-ylamino)cyclohexyl]-acetamide;

2-(3,4-difluoro-phenyl)-N-[cis-4-(4-dimethylamino-pyrimidin-2-ylamino)-cyclohexyl]acetamide;

4-chloro-N-[cis-4-(4-dimethylamino-pyrimidin-2-ylamino)-cyclohexyl]-3-fluorobenzamide;

5-bromo-N-[cis-4-(4-dimethylamino-pyrimidin-2-ylamino)-cyclohexyl]-nicotinamide;
3-chloro-4-fluoro-N-[cis-4-(4-methylamino-pyrimidin-2-ylamino)-cyclohexyl]benzamide;

N-[cis-4-(4-dimethylamino-pyrimidin-2-ylamino)-cyclohexyl]-4-fluoro-benzamide;

3-chloro-N-[cis-4-(4-dimethylamino-pyrimidin-2-ylamino)-cyclohexyl]-5-fluoro-benzamide;

N-[cis-4-(4-dimethylamino-pyrimidin-2-ylamino)-cyclohexyl]-3,4,5-trifluoro-benzamide;
N-[cis-4-(4-dimethylamino-pyrimidin-2-ylamino)-cyclohexylmethyl]-3,4-difluoro-benzamide;

2-(3,4-dichloro-phenoxy)-N-[cis-4-(4-dimethylamino-pyrimidin-2-ylamino)-cyclohexyl]-acetamide;

 $N\hbox{-[cis-4-(4-dimethylamino-pyrimidin-2-ylamino)-cyclohexyl]-2-(3-methoxy-phenoxy)-} \\$ acetamide; and

N-[cis-4-(4-dimethylamino-pyrimidin-2-ylamino)-cyclohexyl]-C-(ethyl-phenyl-amino)-acetamide;

Application No.: 10/812,075

or a pharmaceutically acceptable salt thereof.

64. (previously presented): The compound according to claim 63 selected from the group consisting of:

3-bromo-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-benzamide;

N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2,1,3-benzoxadiazole-

5-carboxamide;

3-chloro-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-benzamide;

4-chloro-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-3-

nitrobenzamide;

3,5-dichloro-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}-

cyclohexyl)benzamide;

3,4-dichloro-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}-

cyclohexyl)benzamide;

N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-3,4-difluorobenzamide;

N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-3-nitrobenzamide;

N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-3-

(trifluoromethoxy)benzamide;

4-bromo-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-3-

methylbenzamide;

N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-3-iodobenzamide;

3-chloro-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-4-

fluorobenzamide;

Application No.: 10/812,075

 $N-(cis-4-\{[4-(dimethylamino)pyrimidin-2-yl]amino\} cyclohexyl]-3,5-dimethoxybenzamide;$

N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-3,5-

bis(trifluoromethyl)benzamide;

N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-4-fluoro-3methylbenzamide;

2-(4-chlorophenoxy)-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}-cyclohexyl)acetamide;

 $N-(cis-4-\{[4-(dimethylamino)pyrimidin-2-yl]amino\} eyelohexyl)-4-fluoro-3-(trifluoromethyl)benzamide;\\$

 $N-(cis-4-\{[4-(dimethylamino)pyrimidin-2-yl]amino\} cyclohexyl)-5-methyl-2-phenyl-2H-1,2,3-triazole-4-carboxamide;$

N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2-(4-methoxyphenoxy)-5-nitrobenzamide;

N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-quinoxaline-2-carboxamide;

 $\label{lem:condition} 2\mbox{-}(3\mbox{-}chlorophenoxy)-N\mbox{-}(cis-4\mbox{-}\{[4\mbox{-}(dimethylamino)pyrimidin-}2\mbox{-}yl]amino\}-cyclohexyl)acetamide;$

 $3-(2,6-dichlorophenyl)-N-(cis-4-\{[4-(dimethylamino)pyrimidin-2-yl]amino\}cyclohexyl)-5-methylisoxazole-4-carboxamide;$

 $N-(cis-4-\{[4-(dimethylamino)pyrimidin-2-yl]amino\} cyclohexyl)-2-(4-methylphenoxy)nicotinamide; \\$

Application No.: 10/812,075

N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-4-[(dipropylamino)sulfonyl]benzamide;

2-(2,3-dihydro-1-benzofuran-5-yl)-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-1,3-thiazole-4-carboxamide;

N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2-(2-thienyl)-1,3-thiazole-4-carboxamide;

5-(4-chloro-2-nitrophenyl)-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2-furamide;

N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-3-methoxy-4nitrobenzamide:

5-bromo-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2-furamide; 5-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}-cyclohexyl)-2-furamide;

 $2-(3,5-di-tert-butyl-4-hydroxyphenyl)-N-(cis-4-\{[4-(dimethylamino)-pyrimidin-2-yl]amino\}cyclohexyl)acetamide;$

4,5-dibromo-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}-cyclohexyl)-2-furamide;

N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2-(1H-indol-3-yl)-4-oxo-4-phenylbutanamide;

 $N-(cis-4-\{[4-(dimethylamino)pyrimidin-2-yl]amino\} cyclohexyl)-2-(1-methyl-1H-indol-3-yl)-4-(4-methylphenyl)-4-oxobutanamide;$

N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2-(2-phenyl-1H-indol-3-yl)acetamide;

Attorney Docket No.: Q74855

AMENDMENT UNDER 37 C.F.R. § 1.111 Application No.: 10/812,075

 $N-(cis-4-\{[4-(dimethylamino)pyrimidin-2-yl]amino\} cyclohexyl)-2-(ethylthio)-2, 2-diphenylacetamide;$

N'-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-N,N-bis[(1S)-1-phenylethyl]phthalamide;

3-(benzyloxy)-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}-cyclohexyl)-4-methoxybenzamide;

N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2-methyl-1,5-diphenyl-1H-pyrrole-3-carboxamide;

 $1-\{2-[(2-chloro-6-fluorobenzyl)thio]ethyl\}-N-(cis-4-\{[4-(dimethylamino)-pyrimidin-2-yl]amino\}cyclohexyl)-2-methyl-5-phenyl-1H-pytrole-3-carboxamide;$

2-[4-(4-chlorophenyl)-2-phenyl-1,3-thiazol-5-yl]-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)acetamide;

 $N-(cis-4-\{[4-(dimethylamino)pyrimidin-2-yl]amino\} cyclohexyl)-5-nitrothiophene-3-carboxamide; \\$

N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-1-methyl-4-nitro-1H-pyrrole-2-carboxamide;

3,5-di-tert-butyl-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}-cyclohexyl)-4-hydroxybenzamide;

 $N-[(cis-4+\{[4-(dimethylamino)pyrimidin-2-yl]amino\}cyclohexyl)methyl]-2, 2-diphenylacetamide; \\$

N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-2-phenylbutanamide;

AMENDMENT UNDER 37 C.F.R. § 1.111

Application No.: 10/812,075

(2E)-N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-methyl]-3-(4-nitrophenyl)acrylamide;

N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-2-(1-naphthyl)acetamide;

 $N-[(cis-4-\{[4-(dimethylamino)pyrimidin-2-yl]amino\}cyclohexyl) methyl]-2-(2,3,6-trichlorophenyl) acetamide;\\$

(2E)-N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-methyl]-3-(3-nitrophenyl)acrylamide;

 $N-[(cis-4-\{[4-(dimethylamino)pyrimidin-2-yl]amino\} cyclohexyl]) methyl]-3-oxoindane-1-carboxamide;$

 $\label{eq:continuous} 2, 2-bis (4-chlorophenyl)-N-[(cis-4-\{[4-(dimethylamino)pyrimidin-2-yl]amino\}cyclohexyl)methyl] acetamide;$

 $N-[(cis-4-\{[4-(dimethylamino)pyrimidin-2-yl]amino\}cyclohexyl)methyl]-3-methyl-4-nitrobenzamide;\\$

N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-3-methoxy-4-nitrobenzamide;

 $N-[(cis-4-\{[4-(dimethylamino)pyrimidin-2-yl]amino\}cyclohexyl)methyl]-2-[2-(trifluoromethoxy)phenyl]acetamide;$

 $N-[(cis-4-\{[4-(dimethylamino)pyrimidin-2-yl]amino\}cyclohexyl)methyl]-9H-xanthene-9-carboxamide;$

 $\label{lem:continuous} 2-(1-benzothien-3-yl)-N-[(cis-4-\{[4-(dimethylamino)pyrimidin-2-yl]amino\}cyclohexyl)methyl]acetamide;$

AMENDMENT UNDER 37 C.F.R. § 1.111

Application No.: 10/812,075

 $\label{eq:N-cyclohexyl} N-[cis-4-(4-dimethylamino-pyrimidin-2-ylamino)-cyclohexyl]-2-(4-fluoro-phenoxy)-nicotinamide;$

N-[cis-4-(4-dimethylamino-pyrimidin-2-ylamino)-cyclohexyl]-C-(ethyl-phenyl-amino)acetamide:

C-[cis-(4-chloro-phenyl)-ethyl-amino]-N-[4-(4-dimethylamino-pyrimidin-2-ylamino)-cyclohexyl]-acetamide;

4-chloro-N-[cis-4-(4-dimethylamino-pyrimidin-2-ylamino)-cyclohexyl]-3-fluorobenzamide:

N-[cis-4-(4-dimethylamino-pyrimidin-2-ylamino)-cyclohexyl]-3,4,5-trifluoro-benzamide;

2-(3,4-dichloro-phenoxy)-N-[cis-4-(4-dimethylamino-pyrimidin-2-ylamino)-cyclohexyl]acetamide;

 $\label{eq:N-constraint} N-[cis-4-(4-dimethylamino-pyrimidin-2-ylamino)-cyclohexyl]-2-(3-methoxy-phenoxy)-acetamide; and$

 $\label{eq:N-continuo} N-[cis-4-(4-dimethylamino-pyrimidin-2-ylamino)-cyclohexyl]-C-(ethyl-phenyl-amino)-acetamide;$

or a pharmaceutically acceptable salt thereof.

65-67. (canceled).

68. (previously presented): The compound according to claim 2 selected from the group consisting of:

N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-N'-mesitylurea;

 $\label{eq:N-constraint} N-(cis-4-\{[4-(dimethylamino)pyrimidin-2-yl]amino\} cyclohexyl)-N'-(2,4,6-trichlorophenyl)urea;$

Application No.: 10/812,075

N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-N'-(2,4,6-tribromophenyl)urea;

 $N-(2,4-dibromo-6-fluorophenyl)-N'-(cis-4-\{[4-(dimethylamino)pyrimidin-2-yl]amino\}cyclohexyl)urea;$

 $N-(cis-4-\{[4-(dimethylamino)pyrimidin-2-yl]amino\}cyclohexyl)-N^{-}\\$ (diphenylmethyl)urea;

N-(4-bromo-2,6-dimethylphenyl)-N'-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)urea;

 $\label{eq:N-constraint} $$N-(cis-4-\{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-N'-[1-(1-naphthyl)ethyl]urea;$

N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-N'-(3,4,5-trimethoxyphenyl)urea;

 $N-(4-chloro-2-methylphenyl)-N'-(cis-4-\{[4-(dimethylamino)pyrimidin-2-yl]amino\}cyclohexyl)urea; \\$

 $N-(5-chloro-2,4-dimethoxyphenyl)-N^-(cis-4-\{[4-(dimethylamino)-pyrimidin-2-yl]amino\}cyclohexyl)urea; \\$

 $\label{lem:n-decomposition} $$N-(4-bromo-2-methylphenyl)-N'-(cis-4-\{[4-(dimethylamino)pyrimidin-2-yl]amino\}cyclohexyl)urea;$

 $\label{eq:N-2-4-4} N-(2,6-dibromo-4-isopropylphenyl)-N'-(cis-4-\{[4-(dimethylamino)-pyrimidin-2-yl]amino\} cyclohexyl)urea;$

 $N-[3-(cyclopentyloxy)-4-methoxyphenyl]-N-(cis-4-\{[4-(dimethylamino)-pyrimidin-2-yl]amino\}cyclohexyl)urea; \\$

Application No.: 10/812,075

N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-N'-(2,6-dimethylphenyl)urea;

N-(2,4-difluorophenyl)-N'-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]urea;

 $N-[(cis-4-\{[4-(dimethylamino)pyrimidin-2-yl]amino\}cyclohexyl)methyl]-N-(2-ethyl-6-methylphenyl)urea;$

 $N-[(cis-4+\{[4-(dimethylamino)pyrimidin-2-yl]amino\}cyclohexyl)methyl]-N-(4-fluorophenyl)urea;$

N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-N'-mesitylurea;

N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-N'-(2,4,6-trichlorophenyl)urea;

 $N-[(cis-4-\{[4-(dimethylamino)pyrimidin-2-yl]amino\} cyclohexyl) methyl]-N'-(2,4,6-tribromophenyl) urea; \\$

 $\label{eq:N-continuous} N-(2,4-dibromo-6-fluorophenyl)-N'-[(cis-4-\{[4-(dimethylamino)pyrimidin-2-yl]amino)cyclohexyl)methyl]urea;$

N-(2,6-diethylphenyl)-N'-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yllamino}cyclohexyl)methyl]urea;

N-[2-chloro-6-(trifluoromethyl)phenyl]-N'-[(cis-4-{[4-(dimethylamino)-pyrimidin-2-yl]amino}cyclohexyl)methyl]urea;

N-(2-chloro-6-methylphenyl)-N'-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]urea;

N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-N'-(2-ethyl-6-isopropylphenyl)urea;

Application No.: 10/812,075

 $N-[(cis-4-\{[4-(dimethylamino)pyrimidin-2-yl]amino\}cyclohexyl)methyl]-N'-(2-isopropyl-6-methylphenyl)urea;$

N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-N'-(2-methyl-3-nitrophenyl)urea;

 $N-[(cis-4-\{[4-(dimethylamino)pyrimidin-2-yl]amino\}cyclohexyl)methyl]-N'-(2-propylphenyl)urea;$

 $N-(2-tert-butyl-6-methylphenyl)-N'-[(cis-4-\{[4-(dimethylamino)pyrimidin-2-yl]amino\}cyclohexyl)methyl]urea;$

N-(2-tert-butylphenyl)-N'-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]urea;

N-(3-chloro-2-methylphenyl)-N'-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]urea;

 $N-(4-bromo-2,6-difluor ophenyl)-N-[(cis-4-\{[4-(dimethylamino) pyrimidin-2-yl]amino\}cyclohexyl]methyl]urea; \\$

 $N-[4-chloro-2-(trifluoromethyl)phenyl]-N'-[(cis-4-\{[4-(dimethylamino)-pyrimidin-2-yl]amino\}cyclohexyl)methyl]urea; \\$

 $\label{eq:N-loss} N-[(cis-4-\{[4-(dimethylamino)pyrimidin-2-yl]amino\}cyclohexyl)methyl]-N'-(diphenylmethyl)urea;$

 $N-(4-bromo-2,6-dimethylphenyl)-N-[(cis-4-\{[4-(dimethylamino)pyrimidin-2-yl]amino\}cyclohexyl)methyl]urea; \\$

N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-N'-(3-methyl-5-phenylisoxazol-4-yl)urea;

AMENDMENT UNDER 37 C.F.R. § 1.111

Application No.: 10/812,075

N-(3,5-dichlorophenyl)-N'-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]-amino}cvclohexyl)methyllurea;

N-(2,3-dichlorophenyl)-N'-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]-amino}cvclohexyl)methyllurea;

N-(2,6-diisopropylphenyl)-N'-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]-amino}cyclohexyl)methyl]urea;

 $N-[(cis-4-\{[4-(dimethylamino)pyrimidin-2-yl]amino\} cyclohexyl)methyl]-N-(2,3-dimethyl-6-nitrophenyl)urea;\\$

 $N-(2,6-dibromo-4-fluorophenyl)-N'-[(cis-4-\{[4-(dimethylamino)pyrimidin-2-yl]amino\}cyclohexyl)methyl]urea;$

N-(2,6-dichlorophenyl)-N'-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]-amino}cyclohexyl)methyl]urea;

 $N-[(cis-4-\{[4-(dimethylamino)pyrimidin-2-yl]amino\} cyclohexyl)methyl]-N'-(2-methoxy-5-methylphenyl)urea;$

 $N-[(cis-4-\{[4-(dimethylamino)pyrimidin-2-yl]amino\} cyclohexyl) methyl]-N'-(2-methyl-6-nitrophenyl) urea; \\$

N-(3,4-difluorophenyl)-N'-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]-amino}cyclohexyl)methyl]urea;

 $N-(3,5-difluor ophenyl)-N-[(cis-4-\{[4-(dimethylamino)pyrimidin-2-yl]-amino\}cyclohexyl)methyl]urea; and \\$

 $N-(3-chloro-4-fluorophenyl)-N'-[(cis-4-\{[4-(dimethylamino)pyrimidin-2-yl]amino\}cyclohexyl)methyl]urea; \\$

or a pharmaceutically acceptable salt thereof.

Application No.: 10/812,075

69-71. (canceled).

72. (previously presented): The compound according to claim 2 selected from the group consisting of:

N-(4-cyanophenyl)-N'-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}-cyclohexyl)thiourea;

N-(2,4-dimethoxyphenyl)-N'-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)thiourea;

N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-N'-(3,4,5-trimethoxyphenyl)thiourea;

N-(3,4-dimethoxyphenyl)-N'-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]-amino}cyclohexyl)thiourea;

 $N-[4-(dimethylamino)-1-naphthyl]-N'-(cis-4-\{[4-(dimethylamino)-pyrimidin-2-yl]amino\}cyclohexyl)thiourea; \\$

N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-N'-(2,4,6-tribromophenyl)thiourea;

N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-N'-mesitylthiourea;

N-(4-bromo-2,6-dimethylphenyl)-N'-(cis-4-{[4-(dimethylamino)pyrimidin-2-

yl]amino}cyclohexyl)thiourea;

 $\label{eq:N-sum} N-(5-chloro-2,4-dimethoxyphenyl)-N'-(cis-4-\{[4-(dimethylamino)-pyrimidin-2-yl]amino\} cyclohexyl) thiourea;$

 $N-(2,4-dibromo-6-fluorophenyl)-N'-(cis-4-\{[4-(dimethylamino)pyrimidin-2-yl]amino\}cyclohexyl)thiourea; and \\$

Application No.: 10/812,075

N-(2,4-dichloro-6-methylphenyl)-N'-(cis-4-{[4-(dimethylamino)pyrimidin-2-

or a pharmaceutically acceptable salt thereof.

73-74. (canceled)

vllamino) cvclohexvl)thiourea;

75. (currently amended): The compound according to claim 2 wherein p is 1 or 2;
R₁ is selected from the group consisting of:

(i) C₁₋₁₆ alkyl, and

C₁₋₁₆ alkyl substituted by substituent(s) independently selected from the group consisting of:

·oxo.

·carbocyclic aryloxy,

 carbocyclic aryloxy substituted by substituent(s) independently selected from the group consisting of:

••halogen,

••C₁₋₅ alkyl,

.. C1.5 alkyl substituted by halogen, and

••C₁₋₅ alkoxy,

·heterocyclyloxy,

 heterocyclyloxy substituted by substituent(s) independently selected from the group consisting of:

··halogen,

••C1-5 alkyl, and

••C₁₋₅ alkyl substituted by halogen,

Application No.: 10/812,075

·mono-carbocyclic arylamino,

 mono-carbocyclic arylamino substituted by substituent(s) independently selected from the group consisting of:

- ··halogen,
- ••C₁₋₅ alkoxy, and
- ••C₁₋₅ alkyl,

·carbocyclic arylsulfinyl,

 carbocyclic arylsulfinyl substituted by substituent(s) independently selected from the group consisting of:

- ..halogen,
- ••C₁₋₅ alkyl, and
- ••C1-5 alkyl substituted by halogen,

·carbocyclic arylsulfonyl,

 carbocyclic arylsulfonyl substituted by substituent(s) independently selected from the group consisting of:

- ..halogen,
- ••C₁₋₅ alkyl, and
- ••C₁₋₅ alkyl substituted by halogen,

·carbocyclic aryl,

 carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:

- ••halogen,
- ••nitro,

Application No.: 10/812,075

••C₁₋₅ alkylcarbonylamino,

••C3-6 cycloalkylcarbonylamino,

••C₁₋₅ alkyl,

••C1-5 alkyl substituted by halogen,

••C₁₋₅ alkoxy, and

••C1-5 alkoxy substituted by halogen, and

·heterocyclyl,

(ii) C3-12 cycloalkyl, and

 C_{3-12} cycloalkyl substituted by substituent(s) independently selected from the group consisting of:

·carbocyclic aryl, and

•carbocyclic aryl substituted by substitutent(s) independently selected from the group consisting of:

- •• C1.5 alkoxy,
- ••halogen,
- ••C₁₋₅ alkyl, and
- ••C₁₋₅ alkyl substituted by halogen,
- (iii) carbocyclic aryl, and

carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:

halogen,

·cyano,

nitro,

Application No.: 10/812,075

•C₁₋₁₀ alkyl,

 ${}^{\circ}\text{C}_{1\text{-}10}$ alkyl substituted by substituent(s) independently selected from the group consisting of:

··halogen, and

••hydroxy,

•C1-9 alkoxy,

 ${}^{\bullet}C_{1.9}$ alkoxy substituted by substituent(s) independently selected from the group consisting of:

..halogen, and

··carbocyclic aryl,

·carboxy,

•C₁₋₅ alkoxycarbonyl,

•di-C1-5 alkylamino,

•C₁₋₅ alkylcarbonylamino,

•C₃₋₆ cycloalkylcarbonylamino,

•C₁₋₅ alkylthio,

•C₁₋₅ alkylsulfinyl,

•C₁₋₅ alkylsulfonyl, •carbocyclic aryl,

(iv) heterocyclyl, and

heterocyclyl substituted by substituent(s) independently selected from the group consisting of:

halogen,

AMENDMENT UNDER 37 C.F.R. § 1.111

Application No.: 10/812,075

·hydroxy,

·amino,

•C₁₋₅ alkyl,

•C1-5 alkyl substituted by halogen,

C₁₋₅ alkoxy,

·carbocyclic aryloxy,

·carbocyclic aryloxy substituted by substituent(s) independently selected

from the group consisting of:

··halogen,

••C1.5 alkyl,

.. C1-5 alkyl substituted by halogen, and

••C1-5 alkoxy,

·heterocyclyloxy,

·heterocyclyloxy substituted by halogen,

·heterocyclyl sulfonyl,

· heterocyclyl sulfonyl substituted by C1-5 alkyl,

·mono-carbocyclic arylamino,

•mono-carbocyclic arylamino substituted by halogen,

•C1-5 alkylthio,

•C1-5 alkylsulfinyl,

·carbocyclic arylsulfinyl,

·carbocyclic arylsulfinyl substituted by halogen,

·carbocyclic arylsulfonyl,

AMENDMENT UNDER 37 C.F.R. § 1.111

Application No.: 10/812,075

 carbocyclic arylsulfonyl substituted by substituents(s) independently selected from the group consisting of:

••halogen,

••C₁₋₅ alkoxy,

••C₁₋₅ alkyl, and

••C1-5 alkyl substituted by halogen,

R2 is selected from the group consisting of:

amino, $C_{1.5}$ alkyl, $C_{1.5}$ alkoxy, -N(R_{2a})(R_{2b}), wherein R_{2a} is hydrogen or $C_{1.5}$ alkyl and R_{2b} is $C_{1.5}$ alkyl or $C_{3.6}$ cycloalkyl;

wherein carbocyclic aryl is phenyl or naphthyl;

heterocyclyl is 3,4-dihydro-1*H*-isoquinolinyl, benzo[1,3]dioxolyl, furyl, isoxazolyl, oxazolyl, pyrazolyl, pyrazinyl, pyridyl, pyrimidyl, or thienyl;

heterocyclyloxy is pyridinyloxy or 1H-pyrazolyloxy;

mono-carbocyclic arylamino is mono-phenylamino; and

halogen is fluoro, chloro, bromo, or iodo;

or a pharmaceutically acceptable salt thereof.

- $\label{eq:compound} \textbf{76.} \qquad \text{(previously presented):} \quad \text{The compound according to claim 75 wherein } R_1 \text{ is} \\$ selected from the group consisting of:
 - (i) C₁₋₁₆ alkyl, and

 C_{1-16} alkyl substituted by substituent(s) independently selected from the group consisting of:

oxo,

·carbocyclic aryl,

Application No.: 10/812,075

•carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:

- ••halogen,
- ••C₁₋₅ alkyl,
- ••C1-5 alkyl substituted by halogen, and
- ••C₁₋₅ alkoxy, and
- ••C1-5 alkoxy substituted by halogen,
- (ii) heterocyclyl, and

heterocyclyl substituted by substituent(s) independently selected from the group consisting of:

·carbocyclic arylsulfinyl, and

·carbocyclic arylsulfinyl substituted by halogen,

Y is -CH2-;

 R_2 is $-N(R_{2a})(R_{2b})$, wherein R_{2a} is C_{1-5} alkyl and R_{2b} is C_{1-5} alkyl;

carbocyclic aryl is phenyl;

heterocyclyl is pyrazinyl; and

halogen is fluoro, chloro, or bromo;

or a pharmaceutically acceptable salt thereof.

group consisting of:

- 77. (previously presented): The compound according to claim 76 wherein $R_{\rm l}$ is selected from the group consisting of:
 - (i) C_{1-16} alkyl, and C_{1-16} alkyl substituted by substituent(s) independently selected from the

Application No.: 10/812,075

·carbocyclic aryl,

 carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:

..halogen, and

••C₁₋₅ alkoxy,

(ii) heterocyclyl, and

heterocyclyl substituted by substituent(s) independently selected from the group consisting of:

·carbocyclic arylsulfinyl, and

·carbocyclic arylsulfinyl substituted by halogen,

 R_2 is $-N(R_{2a})(R_{2b})$, wherein R_{2a} is C_{1-5} alkyl and R_{2b} is C_{1-5} alkyl;

carbocyclic aryl is phenyl;

heterocyclyl is pyrazinyl; and

halogen is fluoro or bromo;

or a pharmaceutically acceptable salt thereof.

78. (previously presented): The compound according to claim 77 wherein R₁ is selected from the group consisting of:

heterocyclyl, and

heterocyclyl substituted by substituent(s) independently selected from the group consisting of:

·carbocyclic arylsulfinyl, and

carbocyclic arylsulfinyl substituted by halogen,

 R_2 is $-N(R_{2a})(R_{2b})$, wherein R_{2a} is C_{1-5} alkyl and R_{2b} is C_{1-5} alkyl;

AMENDMENT UNDER 37 C.F.R. § 1.111

Application No.: 10/812,075

carbocyclic aryl is phenyl;

heterocyclyl is pyrazinyl; and

halogen is fluoro;

or a pharmaceutically acceptable salt thereof.

79. (previously presented): The compound according to any one of claims 76 to 78 wherein p is 1 and T is C₁₋₅ alkyl; R₃ and R₄ are both hydrogen; A and B are both single bonds:

or a pharmaceutically acceptable salt thereof.

80. (previously presented): The compound according to claim 2 selected from the group consisting of:

 $N^2-\{cis.4-[(3,5-dimethoxybenzyl)amino]cyclohexyl\}-N^4,N^4,5-trimethylpyrimidine-2,4-diamine;$

 $\label{eq:N2-special} N^2-\{cis-4-[(3-bromobenzyl)amino]cyclohexyl\}-N^4,N^4,5,6-tetramethylpyrimidine-2,4-diamine;$

 $N^2-\{cis-4-[(3,4-difluor obenzyl)amino] cyclohexyl\}-N^4,N^4,5,6-tetramethyl pyrimidine-2,4-diamine: and$

 $N^2-[cis-4-(\{6-[(3,4-difluorophenyl)sulfinyl]pyrazin-2-yl\}amino)cyclohexyl]-N^4,N^4,5-trimethylpyrimidine-2,4-diamine;$

or a pharmaceutically acceptable salt thereof.

81. (previously presented): The compound according to claim 2 is:

 $N^2-[cis-4-(\{6-[(3,4-difluorophenyl)sulfinyl]pyrazin-2-yl\}amino)cyclohexyl]-N^4,N^4,5-trimethylpyrimidine-2,4-diamine;$

or a pharmaceutically acceptable salt thereof.

Application No.: 10/812,075

82. (currently amended): The compound according to claim 75 wherein R_1 is selected from the group consisting of:

(i) C₁₋₁₆ alkyl, and

 C_{1-16} alkyl substituted by substituent(s) independently selected from the group consisting of:

·carbocyclic aryloxy,

 carbocyclic aryloxy substituted by substituent(s) independently selected from the group consisting of:

••halogen,

••C₁₋₅ alkyl,

••C1-5 alkyl substituted by halogen, and

••C₁₋₅ alkoxy,

·heterocyclyloxy,

 heterocyclyloxy substituted by substituent(s) independently selected from the group consisting of:

••halogen,

••C1-5 alkyl, and

••C1-5 alkyl substituted by halogen,

·mono-carbocyclic arylamino,

 mono-carbocyclic arylamino substituted by substituent(s) independently selected from the group consisting of:

.. halogen,

••C₁₋₅ alkoxy, and

Application No.: 10/812,075

••C₁₋₅ alkyl,

·carbocyclic arylsulfinyl,

 carbocyclic arylsulfinyl substituted by substituent(s) independently selected from the group consisting of:

••halogen,

••C₁₋₅ alkyl, and

••C₁₋₅ alkyl substituted by halogen,

·carbocyclic arylsulfonyl,

 $\label{lem:carbocyclic} \mbox{\bf -carbocyclic arylsulfonyl substituted by substituent} (s) \mbox{ independently} \\ \mbox{\bf selected from the group consisting of:} \\$

••halogen,

••C₁₋₅ alkyl, and

••C1-5 alkyl substituted by halogen,

carbocyclic aryl,

 carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:

••halogen,

••C₁₋₅ alkyl,

••C1-5 alkyl substituted by halogen, and

••C₁₋₅ alkoxy,

(ii) C₃₋₁₂ cycloalkyl, and

C₃₋₁₂ cycloalkyl substituted by substituent(s) independently selected from the group consisting of:

Application No.: 10/812,075

·carbocyclic aryl, and

•carbocyclic aryl substituted by substitutent(s) independently selected from the group consisting of:

- · C₁₋₅ alkoxy,
- ••halogen,
- ••C1-5 alkyl, and
- ••C1-5 alkyl substituted by halogen,
- (iii) carbocyclic aryl, and

carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:

·halogen,

•cyano,

•nitro,

•C₁₋₁₀ alkyl,

•C₁₋₁₀ alkyl substituted by substituent(s) independently selected from the group consisting of:

- ••halogen, and
- ••hydroxy,

•C₁₋₉ alkoxy,

•C1-9 alkoxy substituted by halogen,

·carboxy,

C₁₋₅ alkoxycarbonyl,

•di-C₁₋₅ alkylamino,

Application No.: 10/812,075

•C₁₋₅ alkylcarbonylamino,

•C₃₋₆ cycloalkylcarbonylamino,

•C1-5 alkylsulfonyl, and

·carbocyclic aryl,

(iv) heterocyclyl, and

heterocyclyl substituted by substituent(s) independently selected from the

group consisting of:

·halogen,

hydroxy,

·amino,

•C₁₋₅ alkyl,

•C1-5 alkyl substituted by halogen,

•C₁₋₅ alkoxy,

·carbocyclic aryloxy,

 carbocyclic aryloxy substituted by substituent(s) independently selected from the group consisting of:

••halogen,

••C₁₋₅ alkyl,

••C1-5 alkyl substituted by halogen, and

••C₁₋₅ alkoxy,

·heterocyclyloxy,

heterocyclyloxy substituted by halogen,

·heterocyclyl sulfonyl,

Application No.: 10/812,075

heterocyclyl sulfonyl substituted by C₁₋₅ alkyl,

·mono-carbocyclic arylamino,

*mono-carbocyclic arylamino substituted by halogen,

•C1-5 alkylthio,

C₁₋₅ alkylsulfinyl,

·carbocyclic arylsulfonyl,

•carbocyclic arylsulfonyl substituted by substituents(s) independently

selected from the group consisting of:

••halogen,

••C₁₋₅ alkoxy,

••C₁₋₅ alkyl, and

••C₁₋₅ alkyl substituted by halogen,

Y is -C(O)-;

R2 is selected from the group consisting of:

amino, $C_{1.5}$ alkyl, $C_{1.5}$ alkoxy, $-N(R_{2a})(R_{2b})$, wherein R_{2a} is hydrogen or $C_{1.5}$ alkyl and R_{2b} is $C_{1.5}$ alkyl or $C_{3.6}$ cycloalkyl;

wherein carbocyclic aryl is phenyl;

heterocyclyl is benzo[1,3]dioxolyl, furyl, isoxazolyl, oxazolyl, pyrazolyl,

pyrazinyl, pyridyl, pyrimidyl, or thienyl;

heterocyclyloxy is pyridinyloxy or 1H-pyrazolyloxy;

mono-carbocyclic arylamino is mono-phenylamino; and

halogen is fluoro, chloro, bromo, or iodo;

or a pharmaceutically acceptable salt thereof.

Application No.: 10/812,075

83. (currently amended): The compound according to claim 82 wherein R_1 is selected from the group consisting of:

(i) C₁₋₁₆ alkyl, and

C₁₋₁₆ alkyl substituted by substituent(s) independently selected from the group consisting of:

·carbocyclic aryloxy,

•carbocyclic aryloxy substituted by substituent(s) independently selected from the group consisting of:

••halogen,

••C₁₋₅ alkyl,

••C1-5 alkyl substituted by halogen, and

••C₁₋₅ alkoxy,

heterocyclyloxy,

•heterocyclyloxy substituted by halogen,

·mono-carbocyclic arylamino,

 mono-carbocyclic arylamino substituted by substituent(s) independently selected from the group consisting of:

••halogen,

••C₁₋₅ alkoxy, and

••C₁₋₅ alkyl,

·carbocyclic arylsulfinyl,

 carbocyclic arylsulfinyl substituted by substituent(s) independently selected from the group consisting of: Application No.: 10/812,075

- ··halogen,
- ••C₁₋₅ alkyl, and
- ••C₁₋₅ alkyl substituted by halogen,
- ·carbocyclic arylsulfonyl,
- •carbocyclic arylsulfonyl substituted by substituent(s) independently

selected from the group consisting of:

- ••C₁₋₅ alkyl, and
- ••C1-5 alkyl substituted by halogen,
- ·carbocyclic aryl,
- carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:
 - ••halogen,
 - ••C1-5 alkyl, and
 - ••C₁₋₅ alkyl substituted by halogen,
- (ii) C3-12 cycloalkyl, and
 - C₃₋₁₂ cycloalkyl substituted by substituent(s) independently selected from the group consisting of:
 - ·carbocyclic aryl, and
 - •carbocyclic aryl substituted by substitutent(s) independently selected from the group consisting of:
 - .. C1.5 alkoxy,
 - ••halogen,
 - ••C₁₋₅ alkyl, and

Application No.: 10/812,075

••C1-5 alkyl substituted by halogen,

(iii) carbocyclic aryl, and

carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:

·halogen,

•cyano,

•nitro,

•C₁₋₁₀ alkyl,

 ${}^{\bullet}C_{1\text{-}10}$ alkyl substituted by substituent(s) independently selected from the group consisting of:

..halogen, and

••hydroxy,

•C1-9 alkoxy,

•C1-9 alkoxy substituted by halogen,

carboxy,

•C1-5 alkoxycarbonyl, and

•C1-5 alkylsulfonyl,

(iv) heterocyclyl, and

heterocyclyl substituted by substituent(s) independently selected from the group consisting of:

·halogen,

•C₁₋₅ alkyl,

•C1-5 alkyl substituted by halogen,

AMENDMENT UNDER 37 C.F.R. § 1.111

Application No.: 10/812,075

•C1-5 alkoxy,

·carbocyclic aryloxy,

carbocyclic aryloxy substituted by substituent(s) independently selected

from the group consisting of:

··halogen,

••C1.5 alkyl,

.. C1-5 alkyl substituted by halogen, and

••C₁₋₅ alkoxy,

·heterocyclyloxy,

·heterocyclyloxy substituted by halogen,

*heterocyclyl sulfonyl,

• heterocyclyl sulfonyl substituted by C₁₋₅ alkyl,

·mono-carbocyclic arylamino,

·mono-carbocyclic arylamino substituted by halogen,

•C₁₋₅ alkylthio,

·carbocyclic arylsulfonyl,

•carbocyclic arylsulfonyl substituted by substituents(s) independently

selected from the group consisting of:

••halogen,

••C₁₋₅ alkyl, and

••C1-5 alkyl substituted by halogen,

R2 is selected from the group consisting of:

AMENDMENT UNDER 37 C.F.R. § 1.111

Application No.: 10/812,075

 $C_{1.5} \text{ alkoxy, -N}(R_{2a})(R_{2b}) \text{, wherein } R_{2a} \text{ is hydrogen or } C_{1.5} \text{ alkyl and } R_{2b} \text{ is } C_{1.5}$ alkyl;

wherein carbocyclic aryl is phenyl;

heterocyclyl is benzo[1,3]dioxolyl, furyl, isoxazolyl, oxazolyl, pyrazolyl, pyridyl, or thienyl;

heterocyclyloxy is pyridinyloxy or 1H-pyrazolyloxy;

mono-carbocyclic arylamino is mono-phenylamino; and

halogen is fluoro, chloro, bromo, or iodo;

or a pharmaceutically acceptable salt thereof.

- 84. (currently amended): The compound according to claim 83 wherein R_1 is selected from the group consisting of:
 - (i) C₁₋₁₆ alkyl, and

 C_{1-16} alkyl substituted by substituent(s) independently selected from the group consisting of:

·carbocyclic aryloxy,

 carbocyclic aryloxy substituted by substituent(s) independently selected from the group consisting of:

- ••halogen,
- ••C₁₋₅ alkyl,
- ••C1-5 alkyl substituted by halogen, and
- ••C₁₋₅ alkoxy,

·heterocyclyloxy,

AMENDMENT UNDER 37 C.F.R. § 1.111

Application No.: 10/812,075

•heterocyclyloxy substituted by substituent(s) independently selected from the group consisting of:

··halogen,

••C₁₋₅ alkyl, and

••C1-5 alkyl substituted by halogen,

·mono-carbocyclic arylamino,

 mono-carbocyclic arylamino substituted by substituent(s) independently selected from the group consisting of:

••halogen,

••C₁₋₅ alkoxy, and

••C₁₋₅ alkyl,

·carbocyclic arylsulfinyl,

•carbocyclic arylsulfinyl substituted by substituent(s) independently selected from the group consisting of:

••halogen,

••C₁₋₅ alkyl, and

••C₁₋₅ alkyl substituted by halogen,

·carbocyclic aryl.

•carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:

..halogen,

••C₁₋₅ alkyl, and

••C₁₋₅ alkyl substituted by halogen,

Application No.: 10/812,075

(ii) C3-12 cycloalkyl, and

 $C_{3\text{-}12}$ cycloalkyl substituted by substituent(s) independently selected from

the group consisting of:

carbocyclic aryl, and

 $\hbox{\tt •} carbocyclic \ aryl \ substituted \ by \ substitutent(s) \ independently \ selected$

from the group consisting of:

••C₁₋₅ alkoxy,

••halogen,

••C₁₋₅ alkyl, and

••C₁₋₅ alkyl substituted by halogen,

(iii) carbocyclic aryl, and

carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:

·halogen,

·cyano,

•nitro,

•C₁₋₁₀ alkyl,

•C₁₋₁₀ alkyl substituted by halogen,

•C1-9 alkoxy, and

•C1-9 alkoxy substituted by halogen,

(iv) heterocyclyl, and

heterocyclyl substituted by substituent(s) independently selected from the

group consisting of:

Application No.: 10/812,075

·halogen,

•C₁₋₅ alkyl,

•C1-5 alkyl substituted by halogen,

C₁₋₅ alkoxy,

·carbocyclic aryloxy,

 carbocyclic aryloxy substituted by substituent(s) independently selected from the group consisting of:

••halogen,

••C₁₋₅ alkyl,

••C1-5 alkyl substituted by halogen, and

••C₁₋₅ alkoxy,

•C₁₋₅ alkylthio,

·carbocyclic arylsulfonyl,

·carbocyclic arylsulfonyl substituted by halogen,

R₂ is selected from the group consisting of:

-N(R_{2a})(R_{2b}), wherein R_{2a} is hydrogen or C₁₋₅ alkyl and R_{2b} is C₁₋₅ alkyl;

wherein carbocyclic aryl is phenyl;

heterocyclyl is benzo[1,3]dioxolyl, furyl, pyrazolyl, pyridyl, or thienyl;

heterocyclyloxy is pyridinyloxy or 1H-pyrazolyloxy;

mono-carbocyclic arylamino is mono-phenylamino; and

halogen is fluoro, chloro, bromo, or iodo;

or a pharmaceutically acceptable salt thereof.

AMENDMENT UNDER 37 C.F.R. § 1.111

Application No.: 10/812,075

85. (previously presented): The compound according to any one of claims 82 to 84 wherein p is 1 and T is C₁₋₅ alkyl; R₃ and R₄ are both hydrogen; A is a single bond and B is a single bond or -CH₂-;

or a pharmaceutically acceptable salt thereof.

86. (previously presented): The compound according to claim 2 selected from the group consisting of:

 $\label{eq:N-continuo} N-[(cis-4-\{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino\}cyclohexyl) methyl]-3,5-bis(trifluoromethyl) benzamide;$

 $N-[(cis-4-\{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino\} cyclohexyl) methyl]-3,5-bis(trifluoromethyl) benzamide;$

 $N-[(cis-4-\{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino\} cyclohexyl) methyl]-3, 4-difluorobenzamide;$

3,5-dichloro-N-[(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)methyl]benzamide;

N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)methyl]-3,4-difluorobenzamide;

 $N-[(cis-4-\{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino\} cyclohexyl) methyl]-3,5-dimethoxybenzamide;\\$

N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)methyl]-3-fluoro-4-methylbenzamide;

 $N-[(cis.4-\{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino\} cyclohexyl) methyl]-3-(trifluoromethyl) benzamide;$

AMENDMENT UNDER 37 C.F.R. § 1.111

Application No.: 10/812,075

 $N-[(cis-4-\{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino\} cyclohexyl) methyl]-3-(trifluoromethoxy) benzamide;$

4-bromo-N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-

yl]amino}cyclohexyl)methyl]-3-methylbenzamide;

 $N-[(cis-4-\{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino\} cyclohexyl) methyl]-3-fluoro-4-(trifluoromethyl) benzamide;$

3,5-dichloro-N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-

yl]amino}cyclohexyl)methyl]benzamide;

3.4-dichloro-N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-

yl]amino}cyclohexyl)methyl]benzamide;

4-chloro-N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-

yl]amino}cyclohexyl)methyl]benzamide;

4-chloro-N-[(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-

yl]amino}cyclohexyl)methyl]benzamide;

 $N-[cis-4-(\{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino\} methyl) cyclohexyl]-3,5-dimethoxybenzamide;\\$

4-bromo-N-[cis-4-({[4-(dimethylamino)-5-methylpyrimidin-2-

yl]amino}methyl)cyclohexyl]benzamide;

4-bromo-N-[cis-4-({[4-(dimethylamino)-5-methylpyrimidin-2-

yl]amino}methyl)cyclohexyl]-3-methylbenzamide;

3.5-dichloro-N-[cis-4-({[4-(dimethylamino)-5-methylpyrimidin-2-

yl]amino}methyl)cyclohexyl]benzamide;

AMENDMENT UNDER 37 C.F.R. § 1.111

Application No.: 10/812,075

3,4-dichloro-N-[cis-4-({[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}methyl)cyclohexyl]benzamide;

 $N-[cis-4-(\{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino\} methyl) cyclohexyl]-3,5-bis(trifluoromethyl) benzamide;$

N-[cis-4-({[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}methyl)cyclohexyl]-3,4-difluorobenzamide;

4-bromo-N-[cis-4-({[4-(dimethylamino)-6-methylpyrimidin-2-

yl]amino}methyl)cyclohexyl]benzamide;

4-bromo-N-[cis-4-({[4-(dimethylamino)-6-methylpyrimidin-2-

yl]amino}methyl)cyclohexyl]-3-methylbenzamide;

N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-(2-fluorophenoxy)nicotinamide;

 $N-(cis-4-\{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino\} cyclohexyl)-3,4,5-trimethoxybenzamide;\\$

N-(4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-3-nitrobenzamide:

 $N-(cis-4-\{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino\} cyclohexyl)-2, 2-diphenylacetamide; \\$

N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-4methylbenzamide;

Application No.: 10/812,075

3-chloro-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)benzamide;

N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-3,4-difluorobenzamide;

N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-3-methylbenzamide;

N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-3-methoxybenzamide;

N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-4-fluorobenzamide;

N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-3-methylbenzamide;

N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-3methoxybenzamide;

N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-4-methylbenzamide;

 $N-(cis-4-\{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino\} cyclohexyl)-3, 4-difluorobenzamide;$

3-chloro-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-

yllamino}cyclohexyl)benzamide;

N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-(3-methylphenoxy)nicotinamide;

Application No.: 10/812,075

2-(4-bromophenoxy)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)nicotinamide;

2-(4-chlorophenoxy)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)nicotinamide;

N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-(4-fluorophenoxy)nicotinamide;

N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-(3-fluorophenoxy)nicotinamide;

2-(2-bromophenoxy)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)nicotinamide;

N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-(3methoxyphenoxy)nicotinamide;

N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-(4-methoxyphenoxy)nicotinamide;

N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-(4-iodophenoxy)nicotinamide;

 $\label{lem:condition} 2-(3,4-dichlorophenoxy)-N-(cis-4-\{[5-methyl-4-(methylamino)pyrimidin-2-yl]amino\}cyclohexyl)acetamide;$

2-(2,3-dichlorophenoxy)-N-(cis-4-{[5-methyl-4-(methylamino)pyrimidin-2-yl]amino}cyclohexyl)acetamide;

 $2-[(3,4-difluor ophenyl) sulfonyl]-N-(cis-4-\{[4-(dimethylamino)-5-methyl pyrimidin-2-yl]amino\} cyclohexyl) nicotinamide; \\$

AMENDMENT UNDER 37 C.F.R. § 1.111

Application No.: 10/812,075

N-(cis-4-{[4-(dimethylamino)-5-ethylpyrimidin-2-yl]amino}cyclohexyl)-3,4-difluorobenzamide;

 $N-[cis-4-(\{4-[ethyl(methyl)amino]-5-methylpyrimidin-2-yl\}amino)cyclohexyl]-3, 4-difluorobenzamide;$

 $N-(cis-4-\{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino\} cyclohexyl)-3,5-dimethoxybenzamide;\\$

N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-(2-methoxyphenoxy)nicotinamide;

2-(2-chlorophenoxy)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)nicotinamide;

2-(3-chlorophenoxy)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2yllamino)cyclohexyl)nicotinamide;

 $\label{lem:condition} 2-(3-bromophenoxy)-N-(cis-4-\{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino\}cyclohexyl)nicotinamide;$

 $N-(cis-4-\{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino\} cyclohexyl)-2-[3-(trifluoromethyl)phenoxy]nicotinamide;\\$

N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-(3-fluorophenoxy)acetamide;

N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-(3-methoxyphenoxy)acetamide;

N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-[3-(trifluoromethyl)phenoxy]acetamide;

Application No.: 10/812,075

2-(3-chlorophenoxy)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)acetamide;

2-[(5-chloropyridin-3-yl)oxy]-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)acetamide;

N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)-3,4-difluorobenzamide;

 $\label{lem:cis-4-} 2-(3,4-difluorophenyl)-N-(cis-4-\{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino\} cyclohexyl)-2-hydroxyacetamide;$

 $N-(cis-4-\{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino\} cyclohexyl)-2-hydroxy-2-(4-methoxyphenyl) acetamide;$

 $\label{lem:condition} 2-(2,3-diffluorophenyl)-N-(cis-4-\{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino\}cyclohexyl)-2-hydroxyacetamide;$

 $N-(cis-4-\{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino\} cyclohexyl)-2-hydroxy-2-[3-(trifluoromethyl)phenyl] acetamide; \\$

 $N-(cis-4-\{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino\} cyclohexyl)-2-\{[2-(trifluoromethyl)phenyl]sulfinyl\} acetamide;$

 $\label{lem:condition} 2-[(2-chlorophenyl)sulfinyl]-N-(cis-4-\{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino\}cyclohexyl)acetamide;$

 $2-[(3-bromophenyl)sulfinyl]-N-(cis-4-\{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino\} cyclohexyl)acetamide; \\$

 $2-[(3,4-difluor ophenyl) sulfinyl]-N-(cis-4-\{[4-(dimethylamino)-5-methyl pyrimidin-2-yl]amino\} cyclohexyl) acetamide; \\$

Attorney Docket No.: Q74855

AMENDMENT UNDER 37 C.F.R. § 1.111 Application No.: 10/812,075

N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-3-(trifluoromethyl)benzamide;

N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-3fluorobenzamide;

3-bromo-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-

yl]amino}cyclohexyl)benzamide;

N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-4-(trifluoromethoxy)benzamide;

N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-4fluorobenzamide;

3,4-dichloro-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2yl]amino}cyclohexyl)benzamide;

N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-3,5bis(trifluoromethyl)benzamide;

N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-3,5dimethoxybenzamide;

N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2,4difluorobenzamide;

N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2,5difluorobenzamide;

N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2,3,4trifluorobenzamide;

4-chloro-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-

yl]amino}cyclohexyl)benzamide;

3-cyano-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-

yl]amino}cyclohexyl)benzamide;

4-cvano-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-

yl]amino}cyclohexyl)benzamide;

2-[(3,4-dichlorophenyl)sulfinyl]-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)acetamide;

N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-{[3-(trifluoromethyl)phenyl]sulfinyl}acetamide;

N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}acetamide;

N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-(isopropylthio)nicotinamide;

2-(tert-butylthio)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2yllamino}cyclohexyl)nicotinamide;

N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-(propylthio)nicotinamide;

 $\label{eq:N-constraint} N-(cis-4-\{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino\}cyclohexyl)-3-(methylsulfonyl)benzamide;$

N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-3-fluorobenzamide;

Attorney Docket No.: Q74855

AMENDMENT UNDER 37 C.F.R. § 1.111

Application No.: 10/812,075

N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-3-(trifluoromethyl)benzamide;

3-cyano-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-

yl]amino}cyclohexyl)benzamide;

4-cyano-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-

yl]amino}cyclohexyl)benzamide;

N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-

yl]amino}cyclohexyl)benzamide;

 $N-(cis-4-\{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino\} cyclohexyl)-3-(trifluoromethyl)benzamide; \\$

3-cyano-N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-

yl]amino}cyclohexyl)benzamide;

N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)-3methylbenzamide;

3-chloro-N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-

yl]amino}cyclohexyl)benzamide;

3-bromo-N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-

yl]amino}cyclohexyl)benzamide;

N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)-3,5-dimethoxybenzamide;

 $N-(cis-4-\{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino\} cyclohexyl)-3,5-bis(trifluoromethyl)benzamide;$

Attorney Docket No.: Q74855

AMENDMENT UNDER 37 C.F.R. § 1.111

Application No.: 10/812,075

3,4-dichloro-N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)benzamide;

N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)-4-(trifluoromethoxy)benzamide;

4-cyano-N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-

yl]amino}cyclohexyl)benzamide;

 $N-(cis-4-\{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino\} cyclohexyl)-4-methylbenzamide; \\$

 $N-(cis-4-\{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino\} cyclohexyl)-4-fluorobenzamide; \\$

4-chloro-N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)benzamide;

N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)-2-methoxybenzamide;

4-bromo-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)benzamide;

N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-4-(trifluoromethyl)benzamide;

N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)-3-methoxybenzamide;

5-bromo-N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)-2-furamide:

Application No.: 10/812,075

 $N-(cis-4-\{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino\} cyclohexyl)-5-methylisoxazole-3-carboxamide;\\$

 $\label{lem:condition} 2-(3,5-diffluorophenyl)-N-(cis-4-\{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino\}cyclohexyl)-2-hydroxyacetamide;$

N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)-2-methyl-1,3-oxazole-4-carboxamide;

 $N-(cis-4-\{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino\} cyclohexyl)-2,6-dimethoxynicotinamide; \\$

4-bromo-N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2v]lamino}cyclohexyl)benzamide;

N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)-4-(trifluoromethyl)benzamide;

4-bromo-N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)-3-methylbenzamide;

 $N-(cis-4-\{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino\} cyclohexyl)-3-fluoro-4-methylbenzamide;$

 $N-(cis-4-\{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino\} cyclohexyl)-4-fluoro-3-methylbenzamide;$

 $N-(cis-4-\{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino\} eyclohexyl)-3-ethylbenzamide;$

N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)-3-(trifluoromethoxy)benzamide; 7 C F R 8 1 111 Attorney Docket No.: Q74855

AMENDMENT UNDER 37 C.F.R. § 1.111 Application No.: 10/812,075

5-bromo-N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)nicotinamide;

N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)-5methylthiophene-2-carboxamide

 $N-(cis-4-\{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino\} cyclohexyl)-6-(trifluoromethyl)nicotinamide;$

N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)-3,5-diethoxybenzamide;

N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)-3-ethoxybenzamide;

 $N-(cis-4-\{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino\}cyclohexyl)-3-isopropoxybenzamide;\\$

3,5-dichloro-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)benzamide;

4-bromo-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-3-methylbenzamide;

N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-4-ethoxybenzamide;

N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-4-fluoro-3methylbenzamide;

 $N-(cis-4-\{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino\} cyclohexyl)-3-fluoro-4-methylbenzamide;$

Attorney Docket No.: Q74855

AMENDMENT UNDER 37 C.F.R. § 1.111 Application No.: 10/812,075

 $N-(cis-4-\{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino\} cyclohexyl)-3-ethylbenzamide:$

N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-3,5-bis(trifluoromethyl)benzamide;

 $N-(cis-4-\{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino\} cyclohexyl)-3-fluoro-4-\\ (trifluoromethyl)benzamide;$

 $N-(cis-4-\{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino\} cyclohexyl)-3-fluoro-5-(trifluoromethyl) benzamide;$

3-chloro-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-4-fluorobenzamide:

 $N-(cis-4-\{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino\} cyclohexyl)-4-fluoro-3-methylbenzamide;$

N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-3-fluoro-4-methylbenzamide;

3,5-dichloro-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)benzamide;

 $\label{eq:N-constraint} N-(cis-4-\{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino\} cyclohexyl)-3-(trifluoromethoxy) benzamide;$

 $N-(cis-4-\{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino\} eyclohexyl)-3,5-difluorobenzamide;$

 $\label{lem:comon} 4-bromo-N-(cis-4-\{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino\}cyclohexyl)-3-methylbenzamide;$

Application No.: 10/812,075

 $N-(cis-4-\{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino\} cyclohexyl)-3-ethylbenzamide;\\$

N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-4-(trifluoromethyl)benzamide;

4-bromo-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-

yl]amino}cyclohexyl)benzamide;

 $N-(cis-4-\{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino\}cyclohexyl)-4-ethylbenzamide;\\$

N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-3,5-diethoxybenzamide;

 $N-(cis-4-\{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino\} cyclohexyl)-3-ethoxybenzamide; \\$

N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-3isopropoxybenzamide;

5-bromo-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-

yl]amino}cyclohexyl)nicotinamide;

5-bromo-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-2-furamide;

5-chloro-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-2-furamide;

N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-3-fluoro-5-(trifluoromethyl)benzamide;

Attorney Docket No.: Q74855

AMENDMENT UNDER 37 C.F.R. § 1.111

Application No.: 10/812,075

N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2,2-difluoro-1,3-benzodioxole-5-carboxamide;

N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-3ethoxybenzamide;

 $\label{eq:N-constraint} N-(cis-4-\{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino\} cyclohexyl)-3-isopropoxybenzamide;$

5-bromo-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-furamide;

 $N-(cis-4-\{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino\} cyclohexyl)-3,5-diethoxybenzamide;\\$

 $\label{lem:condition} \mbox{4-chloro-N-(cis-$4-{[4-(dimethylamino)-5-methylpyrimidin-$2-yl]amino}cyclohexyl)-3-(trifluoromethyl)benzamide;} \mbox{4-chloro-N-(cis-$4-{[4-(dimethylamino)-5-methylpyrimidin-$2-yl]amino}cyclohexyl)-3-(trifluoromethyl)benzamide;} \mbox{4-chloro-N-(cis-$4-{[4-(dimethylamino)-5-methylpyrimidin-$2-yl]amino}cyclohexyl)-3-(trifluoromethyl)benzamide;} \mbox{4-chloro-N-(cis-$4-{[4-(dimethylamino)-5-methylpyrimidin-$2-yl]amino}cyclohexyl)-3-(trifluoromethyl)benzamide;} \mbox{4-chloro-N-(cis-$4-{[4-(dimethylamino)-5-methylpyrimidin-$2-yl]amino}cyclohexyl)-3-(trifluoromethyl)benzamide;} \mbox{4-chloro-N-(cis-$4-{[4-(dimethylamino)-5-methylpyrimidin-$2-yl]amino}cyclohexyl)-3-(trifluoromethyl)benzamide;} \mbox{4-chloro-N-(cis-$4-{[4-(dimethylamino)-5-methylpyrimidin-$2-yl]amino}cyclohexyl)-3-(trifluoromethyl)benzamide;} \mbox{4-chloro-N-(cis-$4-{[4-(dimethylamino)-5-methylpyrimidin-$2-yl]amino}cyclohexyl)-3-(trifluoromethyl)benzamide;} \mbox{4-chloro-N-(cis-$4-(dimethylamino)-5-methylpyrimidin-4

5-bromo-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)nicotinamide;

3,4-dichloro-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2yllamino)cyclohexyl)benzamide;

3-chloro-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-4-(trifluoromethoxy)benzamide;

 $N-(cis-4-\{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino\} cyclohexyl)-4-methoxy-3-(trifluoromethyl) benzamide;\\$

 $N-(cis-4-\{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino\} cyclohexyl)-4-methoxy-3-(trifluoromethyl) benzamide;\\$

AMENDMENT UNDER 37 C.F.R. § 1.111

Application No.: 10/812,075

2-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-methylpropanamide;

1-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-

yl]amino}cyclohexyl)cyclopropanecarboxamide;

1-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-

yl]amino}cyclohexyl)cyclobutanecarboxamide;

1-(2,4-dichlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)cyclopropanecarboxamide;

2-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-vllamino}cyclohexyl)-2-methylpropanamide;

1-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)cyclopropanecarboxamide;

1-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)cyclobutanecarboxamide;

 $1-(2,4-dichlorophenyl)-N-(cis-4-\{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino\} cyclohexyl) cyclopropanecarboxamide;$

2-[3,5-bis(trifluoromethyl)phenyl]-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)acetamide;

 $N-(cis-4-\{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino\} cyclohexyl)-4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl] benzamide;$

 $\label{lem:condition} 2-(4-chlorophenyl)-N-(cis-4-\{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino\} cyclohexyl) acetamide;$

Application No.: 10/812,075

N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-1-(4-methylphenyl)cyclopropanecarboxamide;

2-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)propanamide;

2-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yllamino}cyclohexyl)-2-hydroxyacetamide;

N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-1-(4-methoxyphenyl)cyclopropanecarboxamide;

N²-(3-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-N²-methylglycinamide;

 $N^2 - (3,4 - dichlorophenyl) - N - (cis-4 - \{[4 - (dimethylamino) - 5 - methylpyrimidin-2-yl]amino\} cyclohexyl) - N^2 - methylglycinamide;$

 $N-(cis-4-\{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino\} cyclohexyl)-N^2-methyl-N^2-(3-methylphenyl)glycinamide;$

 $\label{eq:N-constraint} N-(cis-4-\{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino\} cyclohexyl)-N^2-(3-fluorophenyl)-N^2-methylglycinamide;$

 $N-(cis-4-\{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino\} cyclohexyl)-N^2-(4-fluorophenyl)-N^2-methylglycinamide;$

 $N^2-(4-chlorophenyl)-N-(cis-4-\{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino\}cyclohexyl)-N^2-methylglycinamide; \\$

 $N^2 - (3,4 - difluor ophenyl) - N - (cis.4 - \{[4 - (dimethylamino) - 5 - methylpyrimidin-2-yl]amino \} cyclohexyl) - N^2 - methylglycinamide;$

Application No.: 10/812,075

 $N-(cis-4-\{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino\}cyclohexyl)-N^2-(3-methoxyphenyl)-N^2-methylglycinamide;$

 $N-(cis-4-\{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino\}cyclohexyl)-N^2-(4-methoxyphenyl)-N^2-methylglycinamide;$

2-[(3,4-difluorophenyl)amino]-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)nicotinamide;

2-(3,4-dichlorophenoxy)-N-(cis-4-{[4-methyl-6-(methylamino)pyrimidin-2-yl]amino}cyclohexyl)acetamide;

 $trans-2-(4-chlorophenyl)-N-(cis-4-\{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino\} cyclohexyl) cyclopropanec arboxamide;$

trans-2-(3-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)cyclopropanecarboxamide;

 $trans-2-(3,4-difluor ophenyl)-N-(cis-4-\{[4-(dimethylamino)-5-methyl pyrimidin-2-yl]amino\} cyclohexyl) cyclopropane carboxamide;$

 $trans-2-(3,4-dichlorophenyl)-N-(cis-4-\{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino\} cyclohexyl) cyclopropanecarboxamide;$

 $trans-2-[3,5-bis(trifluoromethyl)phenyl]-N-(cis-4-\{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino\} cyclohexyl)cyclopropanecarboxamide;$

 $\label{lem:condition} 2-[(4-chlorophenyl)sulfonyl]-N-(cis-4-\{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino\}cyclohexyl)nicotinamide;$

2-[(3-chlorophenyl)sulfonyl]-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yllamino}cyclohexyl)nicotinamide;

Application No.: 10/812,075

 $\label{lem:condition} 2-[(4-bromophenyl)sulfonyl]-N-(cis-4-\{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino\}cyclohexyl)nicotinamide;$

N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}nicotinamide;

N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-{[1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]oxy}acetamide;

 $2-[(2-chlorophenyl)sulfonyl]-N-(cis-4-\{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino\}cyclohexyl)nicotinamide;$

 $\label{eq:continuous} 2-[(3-chlorophenyl)sulfonyl]-N-(cis-4-\{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino)-cyclohexyl)nicotinamide;$

3,4-dichloro-N-{cis-4-[(4-methoxy-5-methylpyrimidin-2-

yl)aminolcyclohexyl}benzamide;

N-[cis-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-cyclohexyl]-2-phenoxy-nicotinamide;

N-[cis-4-(4-dimethylamino-6-methyl-pyrimidin-2-ylamino)-cyclohexyl]-2-phenoxy-nicotinamide;

3-chloro-N-[cis-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-cyclohexyl]-4-fluoro-benzamide;

4-chloro-N-[cis-4-(4-dimethylamino-6-methyl-pyrimidin-2-ylamino)-cyclohexyl]-3-fluoro-benzamide;

3-chloro-N-[cis-4-(4-dimethylamino-6-methyl-pyrimidin-2-ylamino)-cyclohexyl]-5-fluoro-benzamide;

Application No.: 10/812,075

N-[cis-4-(4-dimethylamino-6-methyl-pyrimidin-2-ylamino)-cyclohexyl]-3,4,5-trifluorobenzamide;

3-chloro-4-fluoro-N-[cis-4-(5-methyl-4-methylamino-pyrimidin-2-ylamino)-cyclohexyl]benzamide:

4-chloro-N-[cis-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-cyclohexyl]-3-fluoro-benzamide;

3-chloro-N-[cis-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-cyclohexyl]-5-fluoro-benzamide;

N-[cis-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-cyclohexyl]-3,4,5-trifluoro-benzamide;

 $\label{eq:N-condition} N-[cis-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-cyclohexyl]-3, 5-difluoro-benzamide; and$

 $\label{lem:condition} 2\mbox{-}(3,4\mbox{-}difluoro\mbox{-}phenyl)\mbox{-}N\mbox{-}[cis\mbox{-}4\mbox{-}(4\mbox{-}dimethylamino\mbox{-}5\mbox{-}methyl\mbox{-}pyrimidin-}2\mbox{-}ylamino)\mbox{-}cyclohexyl]\mbox{-}acetamide;$

or a pharmaceutically acceptable salt thereof.

87. (previously presented): The compound according to claim 2 selected from the group consisting of:

N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)methyl]-3,5-bis(trifluoromethyl)benzamide;

 $N-[(cis-4-\{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino\} cyclohexyl) methyl]-3,5-dimethoxybenzamide;\\$

 $N-[(cis-4-\{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino\} cyclohexyl) methyl]-3-(trifluoromethyl) benzamide;\\$

Application No.: 10/812,075

4-bromo-N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-

yl]amino}cyclohexyl)methyl]-3-methylbenzamide;

3.5-dichloro-N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-

yl]amino}cyclohexyl)methyl]benzamide;

3,4-dichloro-N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-

yl]amino}cyclohexyl)methyl]benzamide;

 $3,5\text{-}dichloro\text{-}N\text{-}[cis\text{-}4\text{-}(\{[4\text{-}(dimethylamino})\text{-}5\text{-}methylpyrimidin-}2\text{-}10$

yl]amino}methyl)cyclohexyl]benzamide;

N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-(2-

fluorophenoxy)nicotinamide;

N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-3,4,5-trimethoxybenzamide;

 $N-(4+\{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino\}cyclohexyl)-3-nitrobenzamide;$

N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-2,2-diphenylacetamide;

4-chloro-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-

yl]amino}cyclohexyl)benzamide;

3-chloro-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-

yl]amino}cyclohexyl)benzamide;

N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-3,4-difluorobenzamide:

Application No.: 10/812,075

N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-3-methylbenzamide;

N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-3methoxybenzamide;

N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-4-fluorobenzamide;

N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-3-methylbenzamide;

N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-3-methoxybenzamide;

N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-4methylbenzamide;

 $N-(cis-4-\{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino\} cyclohexyl)-3,4-difluorobenzamide;$

3-chloro-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)benzamide;

 $N-(cis-4-\{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino\} cyclohexyl)-2-(3-methylphenoxy)nicotinamide;$

2-(4-bromophenoxy)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)nicotinamide;

 $\label{lem:condition} 2-(4-chlorophenoxy)-N-(cis-4-\{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino\}cyclohexyl)nicotinamide;$

AMENDMENT UNDER 37 C.F.R. § 1.111 Application No.: 10/812,075

N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-(4-fluorophenoxy)nicotinamide;

N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-(3-fluorophenoxy)nicotinamide;

2-(2-bromophenoxy)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)nicotinamide;

N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-(3-methoxyphenoxy)nicotinamide;

 $N-(cis-4-\{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino\} cyclohexyl)-2-(4-methoxyphenoxy) nicotinamide; \\$

 $N-(cis-4-\{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino\} cyclohexyl)-2-(4-iodophenoxy) nicotinamide;\\$

 $\label{lem:condition} 2-(3,4-dichlorophenoxy)-N-(cis-4-\{[5-methyl-4-(methylamino)pyrimidin-2-yl]amino\}cyclohexyl)acetamide;$

2-(2,3-dichlorophenoxy)-N-(cis-4-{[5-methyl-4-(methylamino)pyrimidin-2-yl]amino}cyclohexyl)acetamide;

 $\label{lem:condition} 2-[(3,4-difluor ophenyl) sulfonyl]-N-(cis-4-\{[4-(dimethylamino)-5-methyl pyrimidin-2-yl]amino\} cyclohexyl) nicotinamide;$

N-[cis-4-({4-[ethyl(methyl)amino]-5-methylpyrimidin-2-yl}amino)cyclohexyl]-3,4-difluorobenzamide;

 $N-(cis-4-\{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino\} cyclohexyl)-3,5-dimethoxybenzamide; \\$

Application No.: 10/812,075

N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-(2-methoxyphenoxy)nicotinamide;

2-(2-chlorophenoxy)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2yllamino}cyclohexyl)nicotinamide;

2-(3-chlorophenoxy)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)nicotinamide;

2-(3-bromophenoxy)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)nicotinamide;

N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-[3-(trifluoromethyl)phenoxy]nicotinamide;

 $N-(cis-4-\{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino\} cyclohexyl)-2-(3-fluorophenoxy) acetamide; \\$

 $N-(cis-4-\{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino\} cyclohexyl)-2-(3-methoxyphenoxy) acetamide; \\$

N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-[3-(trifluoromethyl)phenoxy]acetamide;

 $\label{lem:condition} 2\mbox{-}(3\mbox{-}chlorophenoxy)-N-(cis-4-\{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}\mbox{-}cylohexyl)acetamide;$

 $\label{lem:condition} 2-[(5-chloropyridin-3-yl)oxy]-N-(cis-4-\{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino\}cyclohexyl)acetamide;$

N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)-3,4-difluorobenzamide;

Attorney Docket No.: Q74855

AMENDMENT UNDER 37 C.F.R. § 1.111

Application No.: 10/812,075

 $N-(cis-4-\{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino\} cyclohexyl)-2-hydroxy-2-(4-methoxyphenyl) acetamide;$

2-(2,3-difluorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-hydroxyacetamide;

 $N-(cis-4-\{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino\} cyclohexyl)-2-hydroxy-2-\\ [3-(trifluoromethyl)phenyl]acetamide;$

 $N-(cis-4-\{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino\}cyclohexyl)-2-\{[2-(trifluoromethyl)phenyl]sulfinyl\}acetamide;$

2-[(2-chlorophenyl)sulfinyl]-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)acetamide;

 $\label{lem:cis-4-} 2-[(3-bromophenyl)sulfinyl]-N-(cis-4-\{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino\}cyclohexyl)acetamide;$

 $N-(cis-4-\{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino\}cyclohexyl)-3-\\ (trifluoromethyl)benzamide;$

N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-3-fluorobenzamide;

yl]amino}cyclohexyl)benzamide;

N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-4-(trifluoromethoxy)benzamide;

N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-4-fluorobenzamide;

Application No.: 10/812,075

3,4-dichloro-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-

yl]amino}cyclohexyl)benzamide;

N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-3,5-bis(trifluoromethyl)benzamide;

 $N-(cis-4-\{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino\} cyclohexyl)-3,5-dimethoxybenzamide;\\$

 $N-(cis-4-\{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino\}cyclohexyl)-2, 4-difluorobenzamide;$

 $N-(cis-4-\{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino\} cyclohexyl)-2,5-difluorobenzamide;\\$

N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2,3,4-trifluorobenzamide;

4-chloro-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-

yl]amino}cyclohexyl)benzamide;

3-cyano-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-

yl]amino}cyclohexyl)benzamide;

4-cyano-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-

yl]amino}cyclohexyl)benzamide;

 $N-(cis-4-\{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino\}cyclohexyl)-2-\\ (isopropylthio)nicotinamide;$

N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-(propylthio)nicotinamide;

Application No.: 10/812,075

 $N-(cis-4-\{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino\}cyclohexyl)-3-(trifluoromethyl)benzamide;\\$

3-cyano-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-

yl]amino}cyclohexyl)benzamide;

4-cyano-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-

yl]amino}cyclohexyl)benzamide;

N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)-3-(trifluoromethyl)benzamide;

3-cyano-N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-

yl]amino}cyclohexyl)benzamide;

 $N-(cis-4-\{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino\} cyclohexyl)-3-methylbenzamide; \\$

3-chloro-N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-

yl]amino}cyclohexyl)benzamide;

3-bromo-N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-

yl]amino}cyclohexyl)benzamide;

 $N-(cis-4-\{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino\} cyclohexyl)-3,5-dimethoxybenzamide;$

 $N-(cis-4-\{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino\} cyclohexyl)-3,5-bis(trifluoromethyl)benzamide;$

3,4-dichloro-N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)benzamide;

Application No.: 10/812,075

4-cyano-N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)benzamide;

N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)-4methylbenzamide;

N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)-4fluorobenzamide:

4-chloro-N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)benzamide;

4-bromo-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-

yl]amino}cyclohexyl)benzamide;

 $N-(cis-4-\{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino\} cyclohexyl)-4-\\ (trifluoromethyl)benzamide;$

 $N-(cis-4-\{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino\} cyclohexyl)-3-methoxybenzamide;\\$

5-bromo-N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)-2-furamide;

 $N-(cis-4-\{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino\} cyclohexyl)-2,6-dimethoxynicotinamide; \\$

4-bromo-N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)benzamide;

N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)-4-(trifluoromethyl)benzamide; 4-bromo-N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)-3-methylbenzamide;

 $N-(cis-4-\{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino\} cyclohexyl)-3-fluoro-4-methylbenzamide;\\$

N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)-4-fluoro-3-methylbenzamide;

 $\label{eq:N-constraint} N-(cis-4-\{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino\} cyclohexyl)-3-(trifluoromethoxy) benzamide;$

5-bromo-N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)nicotinamide;

 $N-(cis-4-\{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino\} cyclohexyl)-5-methylthiophene-2-carboxamide;\\$

 $\label{eq:N-constraint} N-(cis-4-\{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino\} cyclohexyl)-3,5-dimethylpyrimidin-2-yl]amino\} cyclohexyl)-3,5-dimethylpyrimidin-3-yl]amino\} cyclohexyllamino\} cyclohe$

 $N-(cis-4-\{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino\} cyclohexyl)-3-ethoxybenzamide;\\$

N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)-3-isopropoxybenzamide;

3,5-dichloro-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)benzamide;

 $\label{lem:comon_section} 4-bromo-N-(cis-4-\{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino\}cyclohexyl)-3-methylbenzamide;$

Attorney Docket No.: O74855

AMENDMENT UNDER 37 C.F.R. § 1.111 Application No.: 10/812,075

methylbenzamide;

N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-4-fluoro-3-

 $N-(cis-4-\{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino\} cyclohexyl)-3-fluoro-4-methylbenzamide; \\$

 $\label{eq:N-constraint} N-(cis-4-\{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino\}cyclohexyl)-3-ethylbenzamide;$

 $N-(cis-4-\{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino\} cyclohexyl)-3,5-bis(trifluoromethyl)benzamide; \\$

 $N-(cis-4-\{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino\} cyclohexyl)-3-fluoro-4-(trifluoromethyl) benzamide; \\$

 $N-(cis-4-\{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino\} cyclohexyl)-3-fluoro-5-(trifluoromethyl) benzamide;$

3-chloro-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-4-fluorobenzamide;

 $N-(cis-4-\{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino\} cyclohexyl)-4-fluoro-3-methylbenzamide; \\$

N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-3-fluoro-4-methylbenzamide;

3,5-dichloro-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yllamino}cyclohexyl)benzamide;

 $\label{eq:N-constraint} N-(cis-4-\{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino\}cyclohexyl)-3-(trifluoromethoxy)benzamide;$

AMENDMENT UNDER 37 C.F.R. § 1.111

Application No.: 10/812,075

N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-3,5-difluorobenzamide:

4-bromo-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-3-methylbenzamide;

 $\label{eq:N-constraint} N-(cis-4-\{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino\} cyclohexyl)-3-ethylbenzamide;$

4-bromo-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-

yl]amino}cyclohexyl)benzamide;

 $N-(cis-4-\{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino\} cyclohexyl)-4-ethylbenzamide;\\$

 $N-(cis-4-\{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino\} cyclohexyl)-3,5-diethoxybenzamide;$

 $N-(cis-4-\{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino\} cyclohexyl)-3-ethoxybenzamide;$

 $N-(cis-4-\{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino\} cyclohexyl)-3-isopropoxybenzamide; \\$

5-bromo-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-

yl]amino}cyclohexyl)nicotinamide;

5-bromo-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-2-furamide;

5-chloro-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-2-furamide;

Application No.: 10/812,075

 $N-(cis-4-\{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino\} cyclohexyl)-3-fluoro-5-(trifluoromethyl)benzamide;$

N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2,2-difluoro-1,3-benzodioxole-5-carboxamide;

 $N-(cis-4-\{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino\} cyclohexyl)-3-ethoxybenzamide; \\$

5-bromo-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-furamide;

 $N-(cis-4-\{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino\} cyclohexyl)-3,5-diethoxybenzamide;$

 $\label{lem:condition} 4-chloro-N-(cis-4-\{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino\} cyclohexyl)-3-(trifluoromethyl)benzamide;$

5-bromo-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)nicotinamide;

3,4-dichloro-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)benzamide;

 $\label{lem:condition} 3-chloro-N-(cis-4+\{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino\}cyclohexyl)-4-(trifluoromethoxy)benzamide;$

 $N-(cis-4-\{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino\} cyclohexyl)-4-methoxy-3-(trifluoromethyl) benzamide;\\$

 $N-(cis-4-\{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino\} cyclohexyl)-4-methoxy-3-(trifluoromethyl) benzamide;$

AMENDMENT UNDER 37 C.F.R. § 1.111

Application No.: 10/812,075

2-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-methylpropanamide

 $1-(4-chlorophenyl)-N-(cis-4-\{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino\} cyclohexyl) cyclopropanecarboxamide;\\$

1-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)cyclobutanecarboxamide;

 $\label{lem:condition} 2-(4-chlorophenyl)-N-(cis-4-\{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino\}cyclohexyl)-2-methylpropanamide$

1-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)cyclopropanecarboxamide;

2-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)acetamide;

 $N-(cis-4-\{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino\} cyclohexyl)-1-(4-methylphenyl)cyclopropanecarboxamide;\\$

 $\label{lem:condition} 2-(4-chlorophenyl)-N-(cis-4-\{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino\}cyclohexyl)propanamide$

Application No.: 10/812,075

2-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yllamino}cyclohexyl)-2-hydroxyacetamide;

N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-1-(4-methoxyphenyl)cyclopropanecarboxamide;

 $\label{eq:normalized} N^2\mbox{-}(3\mbox{-}chlorophenyl)-N-(cis-4-\{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}\mbox{-}cyclohexyl]-N^2\mbox{-}methylglycinamide;}$

 $\label{eq:N2-(3,4-dichlorophenyl)-N-(cis-4-\{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino\}cyclohexyl)-N^2-methylglycinamide;}$

 $N-(cis-4-\{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino\} cyclohexyl)-N^2-methyl-N^2-(3-methylphenyl)glycinamide;$

 $N-(cis-4-\{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino\} cyclohexyl)-N^2-(3-fluorophenyl)-N^2-methylglycinamide;$

 $N-(cis-4-\{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino\}cyclohexyl)-N^2-(4-fluorophenyl)-N^2-methylglycinamide;$

 $\label{eq:N2-decomposition} N^2-(4-chlorophenyl)-N-(cis-4-\{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino\}cyclohexyl)-N^2-methylglycinamide;$

 $N^2\mbox{-}(3,4\mbox{-}difluorophenyl)-N-(cis-4-\{[4\mbox{-}(dimethylamino)\mbox{-}5\mbox{-}methylpyrimidin-}2\mbox{-}yl]amino\}cyclohexyl)-N^2\mbox{-}methylglycinamide;}$

 $N-(cis-4-\{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino\}cyclohexyl)-N^2-(3-methoxyphenyl)-N^2-methylglycinamide;$

 $\label{lem:condition} 2-(3,4-dichlorophenoxy)-N-(cis-4-\{[4-methyl-6-(methylamino)pyrimidin-2-yl]amino\}cyclohexyl)acetamide;$

AMENDMENT UNDER 37 C.F.R. § 1.111

Application No.: 10/812,075

trans-2-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)cyclopropanecarboxamide;

 $trans-2-(3-chlorophenyl)-N-(cis-4-\{[4-(dimethylamino)-5-methylpyrimidin-2-methylpy$

 $yl] amino \} cyclohexyl) cyclopropanec arboxamide;\\$

trans-2-(3,4-difluorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)cyclopropanecarboxamide;

 $trans-2-(3,4-dichlorophenyl)-N-(cis-4-\{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino\}cyclohexyl)cyclopropanecarboxamide;\\$

trans-2-[3,5-bis(trifluoromethyl)phenyl]-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)cyclopropanecarboxamide;

 $\label{lem:condition} 2-[(4-chlorophenyl)sulfonyl]-N-(cis-4-\{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino\}cyclohexyl)nicotinamide;$

 $N-(cis-4-\{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino\} cyclohexyl)-2-\{[1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]oxy\} acetamide;$

 $\label{eq:N-continuous} N-[\mbox{cis-4-}(\mbox{4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-cyclohexyl]-2-phenoxy-nicotinamide;$

N-[cis-4-(4-dimethylamino-6-methyl-pyrimidin-2-ylamino)-cyclohexyl]-2-phenoxy-nicotinamide;

3-chloro-N-[cis-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-cyclohexyl]-4fluoro-benzamide;

4-chloro-N-[cis-4-(4-dimethylamino-6-methyl-pyrimidin-2-ylamino)-cyclohexyl]-3-fluoro-benzamide;

AMENDMENT UNDER 37 C.F.R. § 1.111

Application No.: 10/812,075

3-chloro-N-[cis-4-(4-dimethylamino-6-methyl-pyrimidin-2-ylamino)-cyclohexyl]-5fluoro-benzamide;

N-[cis-4-(4-dimethylamino-6-methyl-pyrimidin-2-ylamino)-cyclohexyl]-3,4,5-trifluorobenzamide;

 $\label{lem:condition} 3-chloro-4-fluoro-N-[cis-4-(5-methyl-4-methylamino-pyrimidin-2-ylamino)-cyclohexyl] benzamide;$

4-chloro-N-[cis-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-cyclohexyl]-3-fluoro-benzamide;

3-chloro-N-[cis-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-cyclohexyl]-5-fluoro-benzamide;

 $\label{eq:N-constraint} N-[cis-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-cyclohexyl]-3,4,5-trifluoro-benzamide;$

 $\label{eq:N-constraint} N-\cite{Cis-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-cyclohexyl]-3, 5-difluoro-benzamide; and$

2-(3,4-difluoro-phenyl)-N-[cis-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-cyclohexyl]-acetamide;

or a pharmaceutically acceptable salt thereof.

- $\textbf{88.} \qquad \textbf{(previously presented):} \ \, \text{The compound according to claim 75 wherein } R_1 \, \text{is} \\ \text{selected from the group consisting of:} \\$
 - (i) C₁₋₁₆ alkyl, and
 C₁₋₁₆ alkyl substituted by substituent(s) independently selected from the group consisting of:
 *carbocyclic aryl,

Application No.: 10/812,075

 carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:

- ••halogen,
- ••nitro.
- ••C₁₋₅ alkylcarbonylamino,
- ••C3-6 cycloalkylcarbonylamino,
- ••C1.5 alkyl,
- ••C₁₋₅ alkyl substituted by halogen,
- ••C₁₋₅ alkoxy, and
- ••C1.5 alkoxy substituted by halogen,
- (ii) C₃₋₁₂ cycloalkyl, and
 C₃₋₁₂ cycloalkyl substituted by carbocyclic aryl,
- (iii) carbocyclic aryl, and carbocyclic aryl substituted by substituent(s) independently selected from

·halogen,

•C₁₋₁₀ alkyl,

•C₁₋₁₀ alkyl substituted by halogen,

•C1-9 alkoxy, and

the group consisting of:

C₁₋₅ alkylthio,

(iv) heterocyclyl,

Y is -C(O)NR5-;

R₂ is selected from the group consisting of:

Application No.: 10/812,075

 $-N(R_{2a})(R_{2b})$, wherein R_{2a} is hydrogen or C_{1-5} alkyl and R_{2b} is C_{1-5} alkyl;

wherein carbocyclic aryl is phenyl or naphthyl;

heterocyclyl is 3,4-dihydro-1H-isoquinolinyl; and

halogen is fluoro, chloro, bromo, or iodo;

or a pharmaceutically acceptable salt thereof.

- $\mbox{89.} \qquad \mbox{(previously presented):} \ \mbox{The compound according to claim 8 wherein R_1 is selected from the group consisting of:}$
 - (i) C₁₋₁₆ alkyl, and

C₁₋₁₆ alkyl substituted by substituent(s) independently selected from the group consisting of:

·carbocyclic aryl,

•carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:

- ••halogen,
- ••nitro,
- ••C₁₋₅ alkyl,
- ••C₁₋₅ alkyl substituted by halogen,
- ••C1-5 alkoxy, and
- ••C₁₋₅ alkoxy substituted by halogen,
- (ii) C_{3-12} cycloalkyl, and $C_{3-12} \ cycloalkyl \ substituted \ by \ carbocyclic \ aryl,$
- (iii) carbocyclic aryl, and

Application No.: 10/812,075

carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:

·halogen,

•C₁₋₁₀ alkyl,

•C1-10 alkyl substituted by halogen, and

C₁₋₉ alkoxy;

R2 is selected from the group consisting of:

-N(R2a)(R2b), wherein R2a is hydrogen or C1-5 alkyl and R2b is C1-5 alkyl;

wherein carbocyclic aryl is phenyl or naphthyl;

heterocyclyl is 3,4-dihydro-1H-isoquinolinyl; and

halogen is fluoro, chloro, bromo, or iodo;

or a pharmaceutically acceptable salt thereof.

90. (previously presented): The compound according to any one of claims 75, 88, and 89 wherein p is 1 and T is $C_{1.5}$ alkyl; R_3 and R_4 are both hydrogen; and A and B are both single bonds; R_5 is hydrogen:

or a pharmaceutically acceptable salt thereof.

91. (previously presented): The compound according to claim 2 selected from the group consisting of:

cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}-N-(3-iodobenzyl)cyclohexanecarboxamide;

 $\label{lem:cis-N-(2,4-dichlorobenzyl)-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino} cyclohexanecarboxamide;}$

Application No.: 10/812,075

 $cis-N-(2,5-dichlorobenzyl)-4-\{[4-(dimethylamino)-6-methylpyrimidin-2-methylpyrimid$

yl]amino}cyclohexanecarboxamide;

cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}-N-(4-

methylbenzyl)cyclohexanecarboxamide;

cis-N-(3,5-dichlorobenzyl)-4-{[4-(dimethylamino)-6-methylpyrimidin-2-

yl]amino}cyclohexanecarboxamide;

cis-N-(3,5-dimethoxybenzyl)-4-{[4-(dimethylamino)-6-methylpyrimidin-2-

yl]amino}cyclohexanecarboxamide;

cis-N-(3-chlorobenzyl)-4-{[4-(dimethylamino)-6-methylpyrimidin-2-

yl]amino}cyclohexanecarboxamide;

cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}-N-[3-

(trifluoromethyl)benzyl]cyclohexanecarboxamide;

 $cis-N-[3,5-bis (trifluoromethyl) benzyl]-4-\{[4-(dimethylamino)-6-methyl pyrimidin-2-methyl benzyl]-4-\{[4-(dimethylamino)-6-methyl byrimidin-2-methyl benzyl]-4-\{[4-(dimethylamino)-6-methyl byrimidin-2-methyl byrimi$

yl]amino}cyclohexanecarboxamide;

cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}-N-(3-

methoxybenzyl)cyclohexanecarboxamide;

cis-N-(4-chlorobenzyl)-4-{[4-(dimethylamino)-6-methylpyrimidin-2-

yl]amino}cyclohexanecarboxamide;

cis-N-(3,4-dichlorobenzyl)-4-{[4-(dimethylamino)-6-methylpyrimidin-2-

yl]amino}cyclohexanecarboxamide;

cis-N-(2,5-difluorobenzyl)-4-{[4-(dimethylamino)-6-methylpyrimidin-2-

yl]amino}cyclohexanecarboxamide;

Application No.: 10/812,075

cis-N-(2,3-difluorobenzyl)-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexanecarboxamide;

 $\label{lem:cis-N-(4-bromo-2-fluorobenzyl)-4-} $$ cis-N-(4-bromo-2-fluorobenzyl)-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexanecarboxamide;$

 $cis-N-(2,4-difluor obenzyl)-4-\{[4-(dimethylamino)-6-methyl pyrimidin-2-methyl pyrimidin$

yl]amino}cyclohexanecarboxamide;

cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}-N-(3-methylbenzyl)cyclohexanecarboxamide;

cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}-N-[2-

(trifluoromethoxy)benzyl]cyclohexanecarboxamide;

cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-N-[(1R)-1-phenylethyl]cyclohexanecarboxamide;

cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-N-[(1S)-1-(4-methylphenyl)ethyl]cyclohexanecarboxamide;

cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-N-[(1R)-1-(4-fluorophenyl)ethyl]cyclohexanecarboxamide;

cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-N-[(1S)-1-(4-fluorophenyl)ethyl]cyclohexanecarboxamide;

cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-N-[(1R)-1-(3-methoxyphenyl)ethyl]cyclohexanecarboxamide;

 $cis-4-\{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino\}-N-[(1S)-1-(3-methoxyphenyl)ethyl]cyclohexanecarboxamide;$

Application No.: 10/812,075

cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-N-[(1S)-1-(4-methoxyphenyl)ethyl]cyclohexanecarboxamide;

cis-N-[(1R)-1-(4-chlorophenyl)ethyl]-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yllamino)cyclohexanecarboxamide;

cis-N-[1-(4-bromophenyl)ethyl]-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexanecarboxamide;

cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-N-[(1R)-1-(4-nitrophenyl)ethyl]cyclohexanecarboxamide;

cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-N-[(1S)-1-(4-nitrophenyl)ethyl]cyclohexanecarboxamide;

cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-N-(3-

fluorophenyl)cyclohexanecarboxamide;

cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-N-(3-methoxyphenyl)cyclohexanecarboxamide;

 $\label{lem:cis-N-(3-chlorophenyl)-4-} $$ cis-N-(3-chlorophenyl)-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexanecarboxamide;$

cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-N-[(1S,2R)-2-

phenylcyclopropyl]cyclohexanecarboxamide; cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-N-[4-

(trifluoromethyl)phenyl]cyclohexanecarboxamide;

cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}-N-[(1R)-1-(3-methoxyphenyl)ethyl]cyclohexanecarboxamide;

Application No.: 10/812,075

 $\label{lem:cis-N-(1S)-1-(4-chlorophenyl)} $$cis-N-[(1S)-1-(4-chlorophenyl)]-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino} cyclohexanecarboxamide;$

cis-N-benzyl-4-{[4-(dimethylamino)-6-methylpyrimidin-2-

yl]amino}cyclohexanecarboxamide;

cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}-N-(4-

fluorobenzyl)cyclohexanecarboxamide;

 $cis-N-(3,4-difluor obenzyl)-4-\{[4-(dimethylamino)-6-methyl pyrimidin-2-methyl pyrimidin$

yl]amino}cyclohexanecarboxamide;

cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}-N-[(1S)-1-(4-

methoxyphenyl)ethyl]cyclohexanecarboxamide;

methoxyphenyl)ethyl]cyclohexanecarboxamide;

cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}-N-[(1R)-1-(4-

fluorophenyl)ethyl]cyclohexanecarboxamide;

 $\label{lem:cis-N-lamino} cis-N-[(1R)-1-(4-chlorophenyl)ethyl]-4-\{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino\}cyclohexanecarboxamide;$

cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-N-[(1S)-1-(1-

naphthyl)ethyl]cyclohexanecarboxamide;

cis-N-[(1R)-1-(4-bromophenyl)ethyl]-4-{[4-(dimethylamino)-5-methylpyrimidin-2-

yllamino}cyclohexanecarboxamide;

cis-N-[(1S)-1-(4-bromophenyl)ethyl]-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yllamino}cyclohexanecarboxamide;

Application No.: 10/812,075

cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-N-{(1S)-1-[4-(trifluoromethoxy)phenyl]ethyl}cyclohexanecarboxamide;

cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-N-[(1R)-1-(2-

fluorophenyl)ethyl]cyclohexanecarboxamide;

cis-N-{(1S)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl}-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexanecarboxamide;

 $\hbox{$4-\{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-N-\{(1S)-1-[2-methylamino)-1-methylpyrimidin-2-yl]amino}]}$

 $(trifluoromethyl) phenyl] ethyl\} cyclohexane carboxamide;\\$

cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-N-{(1R)-1-[4-(trifluoromethoxy)phenyl]ethyl}cyclohexanecarboxamide;

 $\label{lem:cis-N-(1S)-1-(4-chlorophenyl)} cis-N-[(1S)-1-(4-chlorophenyl)]-4-\{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino\} cyclohexanecarboxamide;$

cis-N-[(1R)-1-(4-chlorophenyl)ethyl]-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexanecarboxamide;

 $\label{lem:cis-N-[1-(4-chlorophenyl)-1-methylethyl]-4-[4-(dimethylamino)-5-methylpyrimidin-2-yl] amino} cyclohexanecarboxamide; and$

cis-N-{1-[3,5-bis(trifluoromethyl)phenyl]-1-methylethyl}-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexanecarboxamide;

or a pharmaceutically acceptable salt thereof.

92. (previously presented): The compound according to claim 2 selected from the group consisting of:

Application No.: 10/812,075

 $cis-4-\{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino\}-N-(3-methylpyrimidin-2-yl)]$

iodobenzyl)cyclohexanecarboxamide;

cis-N-(2,4-dichlorobenzyl)-4-{[4-(dimethylamino)-6-methylpyrimidin-2-

yl]amino}cyclohexanecarboxamide;

cis-N-(2,5-dichlorobenzyl)-4-{[4-(dimethylamino)-6-methylpyrimidin-2-

yl]amino}cyclohexanecarboxamide;

cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}-N-(4-

methylbenzyl)cyclohexanecarboxamide;

cis-N-(3,5-dichlorobenzyl)-4-{[4-(dimethylamino)-6-methylpyrimidin-2-

yl]amino}cyclohexanecarboxamide;

cis-N-(3,5-dimethoxybenzyl)-4-{[4-(dimethylamino)-6-methylpyrimidin-2-

yl]amino}cyclohexanecarboxamide;

cis-N-(3-chlorobenzyl)-4-{[4-(dimethylamino)-6-methylpyrimidin-2-

yl]amino}cyclohexanecarboxamide;

cis-N-[3,5-bis(trifluoromethyl)benzyl]-4-{[4-(dimethylamino)-6-methylpyrimidin-2-

yl]amino}cyclohexanecarboxamide;

cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}-N-(3-

methoxybenzyl)cyclohexanecarboxamide;

cis-N-(4-chlorobenzyl)-4-{[4-(dimethylamino)-6-methylpyrimidin-2-

yl]amino}cyclohexanecarboxamide;

cis-N-(3,4-dichlorobenzyl)-4-{[4-(dimethylamino)-6-methylpyrimidin-2-

yl]amino}cyclohexanecarboxamide;

Application No.: 10/812,075

cis-N-(2,5-difluorobenzyl)-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexanecarboxamide;

cis-N-(2,3-difluorobenzyl)-4-{[4-(dimethylamino)-6-methylpyrimidin-2-

yl]amino}cyclohexanecarboxamide;

cis-N-(4-bromo-2-fluorobenzyl)-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexanecarboxamide;

 $\label{lem:cis-N-(2,4-diffuorobenzyl)-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino} cyclohexanecarboxamide;}$

cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}-N-(3-methylbenzyl)cyclohexanecarboxamide;

 $\label{lem:cis-4-} cis-4-\{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino\}-N-[2-(trifluoromethoxy)benzyl]cyclohexanecarboxamide;$

 $\label{lem:cis-4-} cis-4-\{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino\}-N-[(1S)-1-(4-methylphenyl)ethyl]cyclohexanecarboxamide;$

cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-N-[(1R)-1-(4-fluorophenyl)ethyl]cyclohexanecarboxamide;

 $\label{lem:cis-4-lemma-1} cis-4+[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-N-[(1R)-1-(3-methoxyphenyl)ethyl]cyclohexanecarboxamide;$

cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-N-[(1S)-1-(3-methoxyphenyl)ethyl]cyclohexanecarboxamide;

cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-N-[(1S)-1-(4-methoxyphenyl)ethyl]cyclohexanecarboxamide;

Application No.: 10/812,075

cis-N-[(1R)-1-(4-chlorophenyl)ethyl]-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexanecarboxamide;

cis-N-[1-(4-bromophenyl)ethyl]-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexanecarboxamide;

cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-N-[(1R)-1-(4-nitrophenyl)ethyl]cyclohexanecarboxamide;

cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-N-(3-methoxyphenyl)cyclohexanecarboxamide;

cis-N-(3-chlorophenyl)-4-{[4-(dimethylamino)-5-methylpyrimidin-2-y]lamino}cyclohexanecarboxamide;

 $\label{lem:cis-4-} cis-4-\{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino\}-N-[(1S,2R)-2-phenylcyclopropyl]cyclohexanecarboxamide;$

cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-N-[4-(trifluoromethyl)phenyl]cyclohexanecarboxamide;

 $\label{lem:cis-N-(1S)-1-(4-chlorophenyl)} $$ cis-N-[(1S)-1-(4-chlorophenyl)]-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexanecarboxamide; }$

cis-N-(3,4-difluorobenzyl)-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexanecarboxamide;

cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}-N-[(1S)-1-(4-methoxyphenyl)ethyl]cyclohexanecarboxamide;

 $\label{lem:cis-4-} cis-4-\{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}-N-[(1S)-1-(3-methoxyphenyl)ethyl]cyclohexanecarboxamide;$

11 Attorney Docket No.: Q74855

AMENDMENT UNDER 37 C.F.R. § 1.111 Application No.: 10/812,075

Application No.: 10/812,073

cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-N-[(1S)-1-(1-naphthyl)ethyl]cyclohexanecarboxamide;

cis-N-[(1S)-1-(4-bromophenyl)ethyl]-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexanecarboxamide;

 $cis-4-\{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino\}-N-\{(1S)-1-[4-methylpyrimidin-2-yl]amino\}-N-\{(1S)-1-[4-methylpyrimidin-2-yl]amino\}-N-\{(1S)-1-[4-methylpyrimidin-2-yl]amino\}-N-\{(1S)-1-[4-methylpyrimidin-2-yl]amino\}-N-\{(1S)-1-[4-methylpyrimidin-2-yl]amino\}-N-\{(1S)-1-[4-methylpyrimidin-2-yl]amino\}-N-\{(1S)-1-[4-methylpyrimidin-2-yl]amino\}-N-\{(1S)-1-[4-methylpyrimidin-2-yl]amino\}-N-\{(1S)-1-[4-methylpyrimidin-2-yl]amino\}-N-\{(1S)-1-[4-methylpyrimidin-2-yl]amino\}-N-\{(1S)-1-[4-methylpyrimidin-2-yl]amino]-N-\{(1S)-1-[4-methylp$

 $(trifluoromethoxy) phenyl] ethyl \} cyclohexane carboxamide; \\$

 $cis-4-\{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino\}-N-[(1R)-1-(2-yl)]-[($

fluorophenyl)ethyl]cyclohexanecarboxamide;

cis-N-{(1S)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl}-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexanecarboxamide;

4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-N-{(1S)-1-[3-(trifluoromethyl)phenyl]ethyl}cyclohexanecarboxamide;

 $\label{eq:continuous} \mbox{4-{$[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-N-{(1S)-1-[2-methylpyrimidin-2-yl]amino)}} \mbox{-N-{$(1S)-1-[2-methylpyrimidin-2-yl]amino)}} \mbox{-N-{$(1S)-1-[2-methylpyrimi$

cis-N-[(1R)-1-(4-chlorophenyl)ethyl]-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yllamino}cyclohexanecarboxamide;

or a pharmaceutically acceptable salt thereof.

(trifluoromethyl)phenyl]ethyl}cyclohexanecarboxamide; and

- $93. \qquad \text{(previously presented): The compound according to claim 75 wherein R_1 is selected from the group consisting of:}$
 - (i) C₁₋₁₆ alkyl, and

Attorney Docket No.: Q74855

AMENDMENT UNDER 37 C.F.R. § 1.111

Application No.: 10/812,075

C₁₋₁₆ alkyl substituted by substituent(s) independently selected from the group consisting of:

carbocyclic aryl,

 carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:

••halogen,

••C₁₋₅ alkyl, and

.. C1-5 alkyl substituted by halogen,

(ii) C₃₋₁₂ cycloalkyl, and

C₃₋₁₂ cycloalkyl substituted by substituent(s) independently selected from the group consisting of:

·carbocyclic aryl, and

•carbocyclic aryl substituted by halogen,

(iii) carbocyclic aryl, and

carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:

halogen,

•C₁₋₁₀ alkyl,

•C1-10 alkyl substituted by halogen,

•C₁₋₉ alkoxy,

•C₁₋₉ alkoxy substituted by substituent(s) independently selected from the group consisting of:

.. halogen, and

Application No.: 10/812,075

..carbocyclic aryl,

Y is -C(O)NR5-;

 R_2 is -N(R_{2a})(R_{2b}) wherein R_{2a} is hydrogen or C_{1-5} alkyl and R_{2b} is C_{1-5} alkyl; wherein carbocyclic aryl is phenyl; and halogen is fluoro, chloro, bromo, or iodo;

or a pharmaceutically acceptable salt thereof.

- or a plantament, and p
- 94. (previously presented): The compound according to claim 75 or 93 wherein p is 1 or 2 and each T is independently $C_{1.5}$ alkyl; R_3 is hydrogen; R_4 is hydrogen or $C_{1.5}$ alkyl; A and B are both single bonds; R_5 is hydrogen; or a pharmaceutically acceptable salt thereof.
- 95. (previously presented): The compound according to claim 2 selected from the group consisting of:

 $\label{eq:N-constraint} $$N-(3,4-dimethoxyphenyl)-N'-(cis-4-\{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino\}eyclohexyl)urea;$

 $\label{lem:n-decomposition} N-(3-chlorophenyl)-N'-(cis-4-\{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino\}cyclohexyl)-N-methylurea;$

 $\label{eq:N-dichlorophenyl} N'-(cis-4-\{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino\} cyclohexyl)-N-methylurea;$

 $N'-(cis-4-\{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino\} cyclohexyl)-N-methyl-N-(3-methylphenyl)urea; \\$

 $\label{eq:N-constraint} N'-(cis-4-\{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino\} cyclohexyl)-N-methyl-N-(4-methylphenyl)urea;$

N'-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-N-(3-fluorophenyl)-N-methylurea;

AMENDMENT UNDER 37 C.F.R. § 1.111 Application No.: 10/812,075

N'-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-N-(4-fluorophenyl)-N-methylurea;

N-(4-chlorophenyl)-N'-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-N-methylurea;

 $\label{eq:N-diffuor} $$N-(3,4-diffuorophenyl)-N'-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-N-methylurea;$

 $\label{eq:N-constraint} $N'-(cis-4-\{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino} cyclohexyl)-N-(3-methoxyphenyl)-N-methylurea;$

N'-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-N-(4-methoxyphenyl)-N-methylurea;

 $N-\{1-[3,5-bis(trifluoromethyl)phenyl]-1-methylethyl\}-N'-(cis-4-\{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino\}cyclohexyl)urea;$

N-[1-(4-chlorophenyl)-1-methylethyl]-N'-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)urea;

N-[1-(4-chlorophenyl)-1-methylethyl]-N'-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)urea;

N-[1-(4-chlorophenyl)-1-methylethyl]-N'-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-N-methylurea;

N-[1-(4-chlorophenyl)-1-methylethyl]-N'-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-N-methylurea;

N-[1-(4-chlorophenyl)cyclopropyl]-N'-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yllamino}cyclohexyl)-N-methylurea;

Application No.: 10/812,075

N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-N'-(2-methoxyphenyl)urea;

N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-N'-(3-methoxyphenyl)urea;

N-(3,4-dimethoxyphenyl)-N'-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)urea;

 $N-(cis-4-\{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino\} cyclohexyl)-N'-(4-fluorophenyl)urea; \\$

 $N-(3,4-difluorophenyl)-N'-(cis-4-\{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino\}cyclohexyl)urea;$

 $N-(cis-4-\{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino\} cyclohexyl)-N'-[2-(trifluoromethoxy)phenyl]urea;$

 $\label{eq:N-4-local-equation} N-(4-chlorophenyl)-N'-(cis-4-\{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino\} cyclohexyl)urea;$

 $N-[3,5-bis(trifluoromethyl)phenyl]-N'-(cis-4-\{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino\}cyclohexyl)urea; \\$

 $N-(4-bromophenyl)-N'-(cis-4-\{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino\}cyclohexyl)urea;$

N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-N'-(2-methylphenyl)urea;

 $\label{lem:no-benzyl-N'-(cis-4-\{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino-5-methylpyrimidin-2-yl]amino-5-methylpyrimidin-2-yl]amino-5-methylpyrimidin-2-yl]amino-5-methylpyrimidin-3-yl]amino-$

Application No.: 10/812,075

N-[2-chloro-6-(trifluoromethyl)phenyl]-N'-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)urea;

N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-N'-(2,4,6-trichlorophenyl)urea;

 $\label{eq:N-2-4} N-(2,4-dichlorophenyl)-N'-(cis-4-\{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino\}cyclohexyl)-N-methylurea;$

 $\label{eq:N-constraint} $N'-(cis-4-\{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino} $cyclohexyl)-N-methyl-N-[2-(trifluoromethoxy)phenyl]urea;$

N-(4-chlorophenyl)-N'-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-N-ethylurea;

 $N-[3,5-bis(trifluoromethyl)phenyl]-N'-(cis-4-\{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino\}cyclohexyl)-N-ethylurea;$

 $\label{eq:N-constraint} $N'-(cis-4-\{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino} \ cyclohexyl)-N-(2-fluorophenyl)-N-methylurea;$

 $N'-(cis-4-\{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino\} cyclohexyl)-N-ethyl-N-\\[2-(trifluoromethoxy)phenyl]urea;$

 $\label{eq:N-constraint} N'-(cis-4-\{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino\} cyclohexyl)-N-ethyl-N-phenylurea;$

 $N'-(cis-4-\{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino\} cyclohexyl)-N-ethyl-N-(3-methylphenyl)urea; and \\$

1-(2,3-dichloro-phenyl)-3-[cis-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-cyclohexylmethyl]-urea;

or a pharmaceutically acceptable salt thereof.

Application No.: 10/812,075

96. (previously presented): The compound according to claim 2 selected from the group consisting of:

N-(3,4-dimethoxyphenyl)-N'-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)urea;

N-(3-chlorophenyl)-N'-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-N-methylurea;

N-(3,4-dichlorophenyl)-N'-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-N-methylurea;

 $N'-(cis-4-\{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino\} cyclohexyl)-N-methyl-N-(3-methylphenyl)urea; \\$

 $\label{eq:N-constraint} $$N^-(cis-4-\{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}\ eyelohexyl)-N-methyl-N-(4-methylphenyl)urea;$

 $\label{eq:N-constraint} N'-(cis-4-\{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino\} cyclohexyl)-N-(3-fluorophenyl)-N-methylurea;$

 $\label{eq:N-constraint} $N'-(cis-4-\{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino\} cyclohexyl)-N-(4-fluorophenyl)-N-methylurea;$

N-(4-chlorophenyl)-N'-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-N-methylurea;

 $\label{eq:N-3-4-diffuor} $$N-(3,4-diffuorophenyl)-N'-(cis-4-\{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino)-cyclohexyl)-N-methylurea;$

N'-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-N-(3-methoxyphenyl)-N-methylurea;

Application No.: 10/812,075

 $\label{eq:N-(cis-4-{a-dimethylamino}-5-methylpyrimidin-2-yl]amino} cyclohexyl)-N-(4-methoxyphenyl)-N-methylurea;$

N-[1-(4-chlorophenyl)-1-methylethyl]-N'-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)urea;

N-[1-(4-chlorophenyl)-1-methylethyl]-N'-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)urea;

 $\label{eq:N-lemma-2-lemma-2} N-[1-(4-chlorophenyl)-1-methylethyl]-N'-(cis-4-\{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino\}cyclohexyl)-N-methylurea;$

 $N-(cis-4-\{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino\} cyclohexyl)-N^-(4-fluorophenyl)urea; \\$

 $\label{eq:N-cis-4-limit} N-(cis-4-\{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino\} cyclohexyl)-N-[2-(trifluoromethoxy)phenyl]urea;$

 $N-(4-bromophenyl)-N'-(cis-4-\{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino\}cyclohexyl)urea;$

N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-N'-(2-methylphenyl)urea;

N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-N'-(2,4,6-trichlorophenyl)urea;

 $\label{eq:N-2-4-dichlorophenyl} N-(cis-4-\{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino\}cyclohexyl)-N-methylurea;$

 $N'-(cis-4-\{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino\} cyclohexyl)-N-methyl-N-\\[2-(trifluoromethoxy)phenyl]urea;$

AMENDMENT UNDER 37 C.F.R. § 1.111

Application No.: 10/812,075

N-(4-chlorophenyl)-N'-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-vllamino}cyclohexyl)-N-ethylurea;

 $N-[3,5-bis(trifluoromethyl)phenyl]-N'-(cis-4-\{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino\}cyclohexyl)-N-ethylurea;$

 $\label{eq:N-constraint} N'-(cis-4-\{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino\} cyclohexyl)-N-ethyl-N-phenylurea;$

 $\label{eq:N-constraint} $$N'-(cis-4-\{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-N-ethyl-N-(3-methylphenyl)urea; and$

 $1\hbox{-}(2,3\hbox{-}dichloro-phenyl)\hbox{-}3\hbox{-}[cis\hbox{-}4\hbox{-}(4\hbox{-}dimethylamino\hbox{-}5\hbox{-}methyl\hbox{-}pyrimidin-}2\hbox{-}ylamino)\hbox{-}cyclohexylmethyl]\hbox{-}urea;$

or a pharmaceutically acceptable salt thereof.

97-98. (canceled).

- 99. (previously presented): The compound according to claim 75 wherein $R_{\rm l}$ is selected from the group consisting of:
 - carbocyclic aryl, and carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:

•halogen,

•C₁₋₁₀ alkyl, and

•C1-10 alkyl substituted by halogen,

(ii) heterocyclyl,

L is Formula (VII); and

Y is -S(O)2-;

Attorney Docket No.: Q74855

AMENDMENT UNDER 37 C.F.R. § 1.111 Application No.: 10/812,075

 R_2 is $-N(R_{2a})(R_{2b})$ wherein R_{2a} is $C_{1.5}$ alkyl and R_{2b} is $C_{1.5}$ alkyl; wherein carbocyclic aryl is phenyl or naphthyl; heterocyclyl is furyl; and halogen is fluoro, chloro, bromo, or iodo;

or a pharmaceutically acceptable salt thereof.

100. (previously presented): The compound according to any one of claims 75 or 99 wherein p is 1 and T is C₁₋₅ alkyl; R₃ and R₄ are both hydrogen, and A and B are both single bonds:

or a pharmaceutically acceptable salt thereof.

101. (previously presented): The compound according to claim 2 is:

4-chloro-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-

yl]amino}cyclohexyl)benzenesulfonamide;

or a pharmaceutically acceptable salt thereof.

- 102. (canceled).
- 103. (previously presented): A pharmaceutical composition comprising a therapeutically effective amount of a compound according to any one of claims 2, 57, 58, 63, 64, 68, 72, 75-96, and 99-101 in combination with a pharmaceutically acceptable carrier.
 - 104-111. (canceled).
- 112. (previously presented): A method of producing a pharmaceutical composition comprising admixing a compound according to any one of claims 2, 57, 58, 63, 64, 68, 72, 75-96, and 99-101 and a pharmaceutically acceptable carrier.